U.S. patent application number 13/018928 was filed with the patent office on 2011-05-26 for pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as crf antagonists.
This patent application is currently assigned to TAISHO PHARMACEUTICAL CO., LTD.. Invention is credited to Ludo E.J. Kennis, Atsuro NAKAZATO, Dai Nozawa, Taketoshi Okubo, Tomoko Tamita.
Application Number | 20110124862 13/018928 |
Document ID | / |
Family ID | 34971526 |
Filed Date | 2011-05-26 |
United States Patent
Application |
20110124862 |
Kind Code |
A1 |
NAKAZATO; Atsuro ; et
al. |
May 26, 2011 |
PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH
A CYCLIC AMINO GROUP AS CRF ANTAGONISTS
Abstract
[Problem to be Solved] An object of the present invention is to
provide an antagonist against CRF receptors and/or an agonist for
.delta. receptors which is effective as a therapeutic or
prophylactic agent for diseases in which CRF is considered to be
involved, such as depression, anxiety, Alzheimer's disease,
Parkinson's disease, Huntington's chorea, eating disorder,
hypertension, gastrointestinal diseases, drug dependence, cerebral
infarction, cerebral ischemia, cerebral edema, cephalic external
wound, inflammation, immunity-related diseases, alopecia, irritable
bowel syndrome, sleep disorders, epilepsy, dermatitides,
schizophrenia, pain, etc. [Solution] A pyrrolopyrimidine or
pyrrolopyridine derivative substituted with a cyclic amino group
represented by the following formula [I] ##STR00001## has a high
affinity for CRF receptors and/or .delta. receptors, and is
effective against diseases in which CRF is considered to be
involved.
Inventors: |
NAKAZATO; Atsuro; (Tokyo,
JP) ; Okubo; Taketoshi; (Tokyo, JP) ; Nozawa;
Dai; (Tokyo, JP) ; Tamita; Tomoko; (Tokyo,
JP) ; Kennis; Ludo E.J.; (Beerse, BE) |
Assignee: |
TAISHO PHARMACEUTICAL CO.,
LTD.
Tokyo
JP
|
Family ID: |
34971526 |
Appl. No.: |
13/018928 |
Filed: |
February 1, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11630042 |
Jun 16, 2008 |
|
|
|
PCT/JP2005/012152 |
Jun 24, 2005 |
|
|
|
13018928 |
|
|
|
|
Current U.S.
Class: |
544/280 ;
546/113 |
Current CPC
Class: |
A61P 37/00 20180101;
A61P 17/00 20180101; A61P 9/10 20180101; A61P 25/08 20180101; A61P
9/12 20180101; A61P 17/02 20180101; A61P 25/24 20180101; A61P 25/22
20180101; A61P 25/14 20180101; C07D 487/04 20130101; A61P 25/04
20180101; A61P 25/18 20180101; A61P 25/28 20180101; A61P 25/36
20180101; A61P 1/14 20180101; A61P 17/14 20180101; A61P 25/20
20180101; A61P 29/00 20180101; A61P 25/00 20180101; A61P 25/16
20180101; A61P 7/10 20180101; A61P 43/00 20180101; A61P 25/10
20180101; A61P 3/06 20180101; A61P 1/00 20180101; A61P 1/04
20180101; A61P 25/12 20180101; C07D 471/04 20130101 |
Class at
Publication: |
544/280 ;
546/113 |
International
Class: |
C07D 487/04 20060101
C07D487/04; C07D 471/04 20060101 C07D471/04 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 25, 2004 |
JP |
2004-188128 |
Claims
1. A pyrrolopyridine compound substituted with a cyclic amino group
represented by the following formula [I]: ##STR00244## (wherein the
cyclic amino group is represented by the following formula [II]:
##STR00245## in which the cyclic amino group is a 3- to 8-membered
saturated cyclic amine or a 3- to 8-membered saturated cyclic amine
bridged with C.sub.1-5alkylene or
C.sub.1-4alkylene-O--C.sub.1-4alkylene between any different two
carbon atoms of the cyclic amine, which cyclic amine is substituted
with a group represented by
--(CR.sup.1R.sup.2).sub.m--(CHR.sup.3).sub.n--X, R.sup.4 and
R.sup.5 independently on the same or different carbon atoms of the
cyclic amine; X is --CO.sub.2R.sup.9, --CON(R.sup.10)R.sup.11,
--P(.dbd.O)(R.sup.12)R.sup.13 or --S(.dbd.O).sub.kR.sup.14; Y is
CR.sup.15; leis hydrogen, hydroxy, C.sub.1-5alkyl,
C.sub.1-5alkoxy-C.sub.1-5alkyl or hydroxy-C.sub.1-5alkyl; R.sup.2
is hydrogen or C.sub.1-5alkyl; R.sup.3 is hydrogen, cyano,
C.sub.1-5alkyl, C.sub.1-5alkoxy-C.sub.1-5alkyl or
hydroxy-C.sub.1-5alkyl; m is an integer selected from 0, 1, 2, 3, 4
and 5; n is 0 or 1; with the proviso that when X is
--CO.sub.2R.sup.9 or --CON(R.sup.10)R.sup.11, and n is 0, then m is
an integer selected from 1, 2, 3, 4 and 5; R.sup.4 is hydrogen,
hydroxy, hydroxy-C.sub.1-5alkyl, cyano, cyano-C.sub.1-5alkyl or
C.sub.1-5alkyl; R.sup.5 is hydrogen or C.sub.1-5alkyl; R.sup.6 is
hydrogen, halogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-5alkyl, hydroxy, C.sub.1-5alkoxy,
C.sub.3-8cycloalkyloxy or --N(R.sup.16)R.sup.17; R.sup.7 and
R.sup.8 are the same or different, and independently are hydrogen,
halogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-5alkyl, hydroxy, C.sub.1-5alkoxy,
C.sub.3-8cycloalkyloxy, --N(R.sup.18)R.sup.19, --CO.sub.2R.sup.20,
cyano, nitro, C.sub.1-5alkylthio, trifluoromethyl or
trifluoromethoxy; or R.sup.7 and R.sup.8 are taken together to form
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2-- or
--CH.dbd.CH--CH.dbd.CH--; R.sup.9 is hydrogen, C.sub.1-20alkyl,
aryl, C.sub.3-8cycloalkyl or
--CHR.sup.1aOC(.dbd.O)-A.sup.1-R.sup.1b, wherein said
C.sub.1-20alkyl optionally contains one to four double bonds and/or
one to four triple bonds, and/or said C.sub.1-20alkyl is optionally
substituted with one of the substituents selected from the group
consisting of hydroxy, halogen, cyano, C.sub.1-10alkoxy,
C.sub.1-5alkoxycarbonyl, C.sub.3-8cycloalkyl,
--C(.dbd.O)N(R.sup.2a)R.sup.2b, --N(R.sup.3a)R.sup.3b and aryl
which aryl is optionally substituted with one or more substituents,
which are the same or different, selected from the group consisting
of halogen, C.sub.1-5alkyl and C.sub.1-5alkoxy; R.sup.1a is
hydrogen or C.sub.1-5alkyl; A.sup.1 is oxygen or a single bond;
R.sup.1b is C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.2a and R.sup.2b are the
same or different, and independently hydrogen or C.sub.1-3alkyl;
R.sup.3a and R.sup.3b are the same or different, and independently
hydrogen or C.sub.1-3alky; or R.sup.3a and R.sup.3b are taken
together to form --(CH.sub.2).sub.s-A.sup.2-(CH.sub.2).sub.t--;
A.sup.2 is methylene, oxygen, sulfur, NR.sup.4a or a single bond;
R.sup.4a is hydrogen, C.sub.1-5alkyl or benzyl; s and t are the
same or different, and independently an integer selected from 1, 2
or 3; R.sup.10 is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.11 is hydrogen,
C.sub.1-5alkyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-5alkyl or
--CHR.sup.5a--(CH.sub.2).sub.u--C(.dbd.O)R.sup.5b or R.sup.10 and
R.sup.11 are taken together to form
--(CH.sub.2).sub.v-A.sup.3-(CH.sub.2).sub.w--; R.sup.5a is
hydrogen, C.sub.1-5alkyl, aryl or heteroaryl, wherein said
C.sub.1-5alkyl is optionally substituted with one of the
substituents selected from the group consisting of aryl,
heteroaryl, hydroxy, hydroxycarbonyl, 4-hydroxyphenyl,
C.sub.1-5alkoxy, amino, guanidino, mercapto, C.sub.1-5alkylthio or
aminocarbonyl or R.sup.10 and R.sup.5a are taken together to form
--(CH.sub.2).sub.p--; p is 3 or 4; u is 0 or 1; R.sup.5b is
hydroxy, C.sub.1-5alkoxy, benzyloxy or --N(R.sup.6a)R.sup.6b;
R.sup.6a and R.sup.6b are the same or different, and independently
hydrogen or C.sub.1-3alkyl; v and w are the same or different, and
independently an integer selected from 1, 2 or 3; A.sup.3 is
methylene, oxygen, sulfur or NR.sup.7a; R.sup.7a is hydrogen,
C.sub.1-5alkyl or benzyl; R.sup.12 and R.sup.13 are the same or
different, and independently are --OR.sup.21 or
--N(R.sup.22)R.sup.23; R.sup.14 is --OR.sup.21 or
--N(R.sup.22)R.sup.23; k is 1 or 2; R.sup.15 is hydrogen,
C.sub.1-5alkyl, halogen, cyano or --CO.sub.2R.sup.24; R.sup.16 and
R.sup.17 are the same or different, and independently are hydrogen,
C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.18 and R.sup.19 are the
same or different, and independently are hydrogen, C.sub.1-5alkyl,
C.sub.3-8cycloalkyl or C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.20
is hydrogen or C.sub.1-5alkyl; R.sup.21 is hydrogen,
C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.22 and R.sup.23 are the
same or different, and independently are hydrogen, C.sub.1-5alkyl,
C.sub.3-8cycloalkyl or C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.24
is hydrogen or C.sub.1-5alkyl; Ar is aryl or heteroaryl which aryl
or heteroaryl is unsubstituted or substituted with one or more
substituents, which are the same or different, selected from the
group consisting of halogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl,
C.sub.2-5alkenyl, C.sub.2-5alkynyl, C.sub.1-5alkoxy,
C.sub.1-5alkylthio, C.sub.1-5alkylsulfinyl, C.sub.1-5alkylsulfonyl,
cyano, nitro, hydroxy, --CO.sub.2R.sup.25, --C(.dbd.O)R.sup.26,
--CON(R.sup.27)R.sup.28, --OC(.dbd.O)R.sup.29,
--NR.sup.30CO.sub.2R.sup.31, --S(O).sub.rN(R.sup.32)R.sup.33,
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy,
methylenedioxy, ethylenedioxy and --N(R.sup.34)R.sup.35; R.sup.25
is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.26 is hydrogen or
C.sub.1-5alkyl; R.sup.27 and R.sup.28 are the same or different,
and independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl
or C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.29 is hydrogen or
C.sub.1-5alkyl; R.sup.30 is hydrogen or C.sub.1-5alkyl; R.sup.31 is
hydrogen or C.sub.1-5alkyl; R.sup.32 and R.sup.33 are the same or
different, and independently are hydrogen, C.sub.1-5alkyl,
C.sub.3-8cycloalkyl or C.sub.3-8cycloalkyl-C.sub.1-5alkyl; r is 1
or 2; R.sup.34 and R.sup.35 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl), individual isomers thereof,
racemic or non-racemic mixtures of isomers thereof or N-oxide
thereof, or pharmaceutically acceptable salts and hydrates
thereof.
2. A pyrrolopyridine compound substituted with a cyclic amino group
represented by the following formula [I]: ##STR00246## (wherein the
cyclic amino group is represented by the following formula [II]:
##STR00247## in which the cyclic amino group is a 3- to 8-membered
saturated cyclic amine or a 3- to 8-membered saturated cyclic amine
bridged with C.sub.1-5alkylene or
C.sub.1-4alkylene-O--C.sub.1-4alkylene between any different two
carbon atoms of the cyclic amine, which cyclic amine is substituted
with a group represented by
--(CR.sup.1R.sup.2).sub.m--(CHR.sup.3).sub.n--X, R.sup.4 and
R.sup.5 independently on the same or different carbon atoms of the
cyclic amine; X is --CO.sub.2R.sup.9, --CON(R.sup.10)R.sup.11,
--P(.dbd.O)(R.sup.12)R.sup.13 or --S(.dbd.O).sub.kR.sup.14; Y is N
or CR.sup.15; R.sup.1 is hydrogen, hydroxy, C.sub.1-5alkyl,
C.sub.1-5alkoxy-C.sub.1-5alkyl or hydroxy-C.sub.1-5alkyl; R.sup.2
is hydrogen or C.sub.1-5alkyl; R.sup.3 is hydrogen, cyano,
C.sub.1-5alkyl, C.sub.1-5alkoxy-C.sub.1-5alkyl or
hydroxy-C.sub.1-5alkyl; m is an integer selected from 0, 1, 2, 3, 4
and 5; n is 0 or 1; with the proviso that when X is
--CO.sub.2R.sup.9 or --CON(R.sup.10)R.sup.11, and n is 0, then m is
an integer selected from 1, 2, 3, 4 and 5; R.sup.4 is hydrogen,
hydroxy, hydroxy-C.sub.1-5alkyl, cyano, cyano-C.sub.1-5alkyl or
C.sub.1-5alkyl; R.sup.5 is hydrogen or C.sub.1-5alkyl; R.sup.6 is
hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-5alkyl, hydroxy, C.sub.1-5alkoxy,
C.sub.3-8cycloalkyloxy or --N(R.sup.16)R.sup.17; R.sup.7 and
R.sup.8 are the same or different, and independently are hydrogen,
halogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-5alkyl, hydroxy, C.sub.1-5alkoxy,
C.sub.3-8cycloalkyloxy, --N(R.sup.18)R.sup.19, --CO.sub.2R.sup.20,
cyano, nitro, C.sub.1-5alkylthio, trifluoromethyl or
trifluoromethoxy; or R.sup.7 and R.sup.8 are taken together to form
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2-- or
--CH.dbd.CH--CH.dbd.CH--; R.sup.9 is hydrogen, C.sub.1-10alkyl,
C.sub.3-8cycloalkyl or C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.10
and R.sup.11 are the same or different, and independently are
hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.12 and R.sup.13 are the
same or different, and independently are --OR.sup.21 or
--N(R.sup.22)R.sup.23; R.sup.14 is --OR.sup.21 or
--N(R.sup.22)R.sup.23; k is 1 or 2; R.sup.15 is hydrogen,
C.sub.1-5alkyl, halogen, cyano or --CO.sub.2R.sup.24; R.sup.16 and
R.sup.17 are the same or different, and independently are hydrogen,
C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.18 and R.sup.19 are the
same or different, and independently are hydrogen, C.sub.1-5alkyl,
C.sub.3-8cycloalkyl or C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.20
is hydrogen or C.sub.1-5alkyl; R.sup.21 is hydrogen,
C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.22 and R.sup.23 are the
same or different, and independently are hydrogen, C.sub.1-5alkyl,
C.sub.3-8cycloalkyl or C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.24
is hydrogen or C.sub.1-5alkyl; Ar is aryl or heteroaryl which aryl
or heteroaryl is unsubstituted or substituted with 1 or more
substituents, which are the same or different, selected from the
group consisting of halogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl,
C.sub.2-5alkenyl, C.sub.2-5alkynyl, C.sub.1-5alkoxy,
C.sub.1-5alkylthio, C.sub.1-5alkylsulfinyl, C.sub.1-5alkylsulfonyl,
cyano, nitro, hydroxy, --CO.sub.2R.sup.25, --C(.dbd.O)R.sup.26,
--CON(R.sup.27)R.sup.28, --OC(.dbd.O)R.sup.29,
--NR.sup.30CO.sub.2R.sup.31, --S(O).sub.rN(R.sup.32)R.sup.33,
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy,
methylenedioxy, ethylenedioxy and --N(R.sup.34)R.sup.35; R.sup.25
is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.26 is hydrogen or
C.sub.1-5alkyl; R.sup.27 and R.sup.28 are the same or different,
and independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl
or C.sub.3-8cycloalkyl-C.sub.1-5alkyl; R.sup.29 is hydrogen or
C.sub.1-5alkyl; R.sup.30 is hydrogen or C.sub.1-5alkyl; R.sup.31 is
hydrogen or C.sub.1-5alkyl; R.sup.32 and R.sup.33 are the same or
different, and independently are hydrogen, C.sub.1-5alkyl,
C.sub.3-8cycloalkyl or C.sub.3-8cycloalkyl-C.sub.1-5alkyl; r is 1
or 2; R.sup.34 and R.sup.35 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl), individual isomers thereof,
racemic or non-racemic mixtures of isomers thereof or N-oxide
thereof, or pharmaceutically acceptable salts and hydrates
thereof.
3.-8. (canceled)
9. The pyrrolopyridine compound substituted with the cyclic amino
group according to claim 2 represented by formula [I], wherein m is
an integer selected from 1, 2, 3, 4 and 5; n is 0; R.sup.1,
R.sup.2, R.sup.4 and R.sup.5 are hydrogen; R.sup.15 is hydrogen or
halogen; X, the cyclic amino group, R.sup.6, R.sup.7, R.sup.8 and
Ar are as defined in claim 2; individual isomers thereof or racemic
or non-racemic mixtures of isomers thereof, or pharmaceutically
acceptable salts and hydrates thereof.
10. The pyrrolopyridine compound substituted with the cyclic amino
group according to claim 2 represented by formula [I], wherein X is
as defined in claim 2; Y is CH; the cyclic amino group is a 4- to
7-membered saturated cyclic amine; m is an integer selected from 1,
2 and 3; n is 0; R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are
hydrogen; R.sup.6 is C.sub.1-5alkyl; R.sup.7 and R.sup.8 are the
same or different, and independently are hydrogen or
C.sub.1-5alkyl; Ar is phenyl which phenyl is substituted with two
or three substituents, which are the same or different, selected
from the group consisting of halogen, C.sub.1-3alkyl,
C.sub.1-3alkoxy, C.sub.1-3alkylthio, trifluoromethyl,
trifluoromethoxy and --N(R.sup.34)R.sup.35 (wherein R.sup.34 and
R.sup.35 are the same or different, and independently are hydrogen
or C.sub.1-3alkyl); individual isomers thereof or racemic or
non-racemic mixtures of isomers thereof, or pharmaceutically
acceptable salts and hydrates thereof.
11. The pyrrolopyridine compound substituted with the cyclic amino
group according to claim 2 represented by formula [I], wherein X is
--CO.sub.2H, --CONH.sub.2, --P(.dbd.O)(OH).sub.2 or
--S(.dbd.O).sub.2OH; Y is CH; the cyclic amino group is a
6-membered saturated cyclic amine; m is an integer selected from 1,
2 and 3; n is 0; R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are
hydrogen; R.sup.6 is C.sub.1-3alkyl; R.sup.7 and R.sup.8 are the
same or different, and independently are hydrogen or
C.sub.1-3alkyl; Ar is phenyl which phenyl is substituted with two
or three substituents, which are the same or different, selected
from the group consisting of chloro, bromo, C.sub.1-3alkoxy,
C.sub.1-3alkylthio, trifluoromethyl, trifluoromethoxy and
dimethylamino; individual isomers thereof or racemic or non-racemic
mixtures of isomers thereof, or pharmaceutically acceptable salts
and hydrates thereof.
12. The pyrrolopyridine compound substituted with the cyclic amino
group according to claim 2 represented by formula [I], wherein X is
--CO.sub.2H; Y is CH; the cyclic amino group is a 6-membered
saturated cyclic amine; m is an integer selected from 1, 2 and 3; n
is 0; R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are hydrogen; R.sup.6
is methyl; R.sup.7 and R.sup.8 are the same or different, and
independently are hydrogen or methyl; Ar is phenyl which phenyl is
substituted with two or three substituents, which are the same or
different, selected from the group consisting of chloro, bromo,
C.sub.1-3alkoxy, C.sub.1-3alkylthio and trifluoromethyl; individual
isomers thereof or racemic or non-racemic mixtures of isomers
thereof, or pharmaceutically acceptable salts and hydrates
thereof.
13. Compounds represented by formula [1] according to claim 1,
which compounds are selected from the group consisting of
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]pyri-
din-4-yl]-piperidin-4-yl}-acetic acid,
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid,
{1-[1-(4-chloro-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]pyr-
idin-4-yl]-piperidin-4-yl}-acetic acid,
{1-[1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridi-
n-4-yl]-piperidin-4-yl}-acetic acid,
{1-[1-(2,6-dibromo-4-isopropyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]p-
yridin-4-yl]-piperidin-4-yl}-acetic acid,
{1-[1-(2,6-dibromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyri-
din-4-yl]-piperidin-4-yl}-acetic acid,
{1-[3,6-dimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-
-piperidin-4-yl}-acetic acid,
{1-[1-(4-bromo-2,6-dichloro-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid,
{1-[3,6-dimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl-
]-piperidin-4-yl}-acetic acid,
{1-[1-(2,6-dibromo-4-chloro-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid,
{1-[1-(2-bromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin--
4-yl]-piperidin-4-yl}-acetic acid,
{1-[1-(4-isopropyl-2-methylsulfanyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b-
]pyridin-4-yl]-piperidin-4-yl}-acetic acid,
{1-[1-(2,4-dibromo-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-pi-
peridin-4-yl}-acetic acid,
3-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]py-
ridin-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(4-chloro-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]p-
yridin-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyri-
din-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(2,6-dibromo-4-isopropyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b-
]pyridin-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(2,6-dibromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]py-
ridin-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(4-bromo-2,6-dichloro-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[3,6-dimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo[2,3-b]pyridin-4--
yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(2,6-dibromo-4-chloro-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyr-
idin-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(2-bromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridi-
n-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(4-isopropyl-2-methylsulfanyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-
-b]pyridin-4-yl]-piperidin-4-yl}-propionic acid,
3-{1-[1-(2,4-dibromo-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]--
piperidin-4-yl}-propionic acid,
4-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]py-
ridin-4-yl]-piperidin-4-yl}-butyric acid,
4-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-butyric acid,
{8-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-8-aza-bicyclo[3.2.1]oct-3-yl}-acetic acid,
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-3-yl}-acetic acid,
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-acetamide,
3-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-propionamide,
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-ylmethyl}-phosphonic acid,
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-methanesulfonic acid,
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-ethanesulfonic acid,
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-ethanesulfonic acid amide,
2,2-dimethyl-propionic acid
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]-
pyridin-4-yl]-piperidin-4-yl}-acetoxymethyl ester, and
(S)-2-(2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3--
b]pyridin-4-yl]-piperidin-4-yl}-acetylamino)-3-phenyl-propionic
acid ethyl ester.
14. An antagonist for CRF receptors, comprising a pyrrolopyridine
compound substituted with a cyclic amino group, a pharmaceutically
acceptable salt thereof or its hydrate according to claim 1, as an
active ingredient.
15. (canceled)
Description
[0001] This is a divisional of application Ser. No. 11/630,042
filed Jun. 16, 2008, which is a National Stage application of PCT
Application No. PCT/JP05/12152, filed Jun. 24, 2005, which claims
priority of Japanese Application No. 2004-188128, filed Jun. 25,
2004, the disclosure of each of which is incorporated herein by
reference in its entirety.
DETAILED DESCRIPTION OF THE INVENTION
Technical Field
[0002] The present invention relates to a therapeutic agent for
diseases in which corticotropin releasing factor (CRF) is
considered to be involved, such as depression, anxiety, Alzheimer's
disease, Parkinson's disease, Huntington's chorea, eating disorder,
hypertension, gastrointestinal diseases, drug dependence, cerebral
infarction, cerebral ischemia, cerebral edema, cephalic external
wound, inflammation, immunity-related diseases, alopecia, irritable
bowel syndrome, sleep disorders, epilepsy, dermatitides,
schizophrenia, pain, etc.
DESCRIPTION OF THE PRIOR ART
[0003] CRF is a hormone comprising 41 amino acids (Science, 213,
1394-1397, 1981; and J. Neurosci., 7, 88-100, 1987), and it is
suggested that CRF plays a core role in biological reactions
against stresses (Cell. Mol. Neurobiol., 14, 579-588, 1994;
Endocrinol., 132, 723-728, 1994; and Neuroendocrinol. 61, 445-452,
1995). For CRF, there are the following two paths: a path by which
CRF acts on peripheral immune system or sympathetic nervous system
through hypothalamus-pituitary-adrenal system, and a path by which
CRF functions as a neurotransmitter in central nervous system (in
Corticotropin Releasing Factor: Basic and Clinical Studies of a
Neuropeptide, pp. 29-52, 1990). Intraventricular administration of
CRF to hypophysectomized rats and normal rats causes an
anxiety-like symptom in both types of rats (Pharmacol. Rev., 43,
425-473, 1991; and Brain Res. Rev., 15, 71-100, 1990). That is,
there are suggested the participation of CRF in
hypothalamus-pituitary-adrenal system and the pathway by which CRF
functions as a neurotransmitter in central nervous system.
[0004] The review by Owens and Nemeroff in 1991 summarizes diseases
in which CRF is involved (Pharmacol. Rev., 43, 425-474, 1991). That
is, CRF is involved in depression, anxiety, Alzheimer's disease,
Parkinson's disease, Huntington's chorea, eating disorder,
hypertension, gastrointestinal diseases, drug dependence,
inflammation, immunity-related diseases, etc. It has recently been
reported that CRF is involved also in epilepsy, cerebral
infarction, cerebral ischemia, cerebral edema, and cephalic
external wound (Brain Res. 545, 339-342, 1991; Ann. Neurol. 31,
48-498, 1992; Dev. Brain Res. 91, 245-251, 1996; and Brain Res.
744, 166-170, 1997). Accordingly, antagonists against CRF receptors
are useful as therapeutic agents for the diseases described
above.
[0005] Opioid analgesics are well known for their ability to reduce
the perception of pain without a loss of consciousness. At least
three major types of opioid receptors (.delta., .mu., .kappa.) are
involved in the modulation of a variety of opioid effects. In the
field of opioid research, selective agonists for the .delta.-opioid
receptor have shown promising therapeutic potential as analgesics
without the adverse side effects associated with morphine and other
opioid drugs which are selective for the .mu.-opioid receptor.
There are several lines of evidence showing that stimulation of
.delta.-opioid receptor could alleviate pain process (J. Pharmacol.
Exp. Ther. 307, 1079-1089, 2003).
[0006] WO02/002549, WO00/053604 and WO04/058767 disclose
pyrrolopyridine and pyrrolopyrimidine derivatives as CRF receptor
antagonists. However, none disclose the compounds provided in the
present invention.
PROBLEM(S) TO BE SOLVED BY INVENTION
[0007] An object of the present invention is to provide an
antagonist against CRF receptors and/or an agonist for 8 receptors
which is effective as a therapeutic or prophylactic agent for
diseases in which CRF is considered to be involved, such as
depression, anxiety, Alzheimer's disease, Parkinson's disease,
Huntington's chorea, eating disorder, hypertension,
gastrointestinal diseases, drug dependence, cerebral infarction,
cerebral ischemia, cerebral edema, cephalic external wound,
inflammation, immunity-related diseases, alopecia, irritable bowel
syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia,
pain, etc.
MEANS FOR SOLVING PROBLEM
[0008] The present inventors earnestly investigated
pyrrolopyrimidine and pyrrolopyridine derivatives substituted with
a cyclic amino group that have a high affinity for CRF receptors
and/or 8 receptors, whereby the present invention has been
accomplished.
[0009] The present invention is pyrrolopyrimidine and
pyrrolopyridine derivatives substituted with a cyclic amino group
explained below.
[0010] A pyrrolopyrimidine or pyrrolopyridine derivative
substituted with a cyclic amino group represented by the following
formula [I]:
##STR00002##
(wherein the cyclic amino group is represented by the following
formula [II]:
##STR00003##
[0011] in which the cyclic amino group is a 3- to 8-membered
saturated cyclic amine or a 3- to 8-membered saturated cyclic amine
bridged with C.sub.1-5alkylene or
C.sub.1-4alkylene-O--C.sub.1-4alkylene between any different two
carbon atoms of the cyclic amine, which cyclic amine is substituted
with a group represented by
--(CR.sup.1R.sup.2).sub.m--(CHR.sup.3).sub.n--X, R.sup.4 and
R.sup.5 independently on the same or different carbon atoms of the
cyclic amine;
[0012] X is --CO.sub.2R.sup.9, --CON(R.sup.10)R.sup.11,
--P(.dbd.O)(R.sup.12)R.sup.13 or --S(.dbd.O).sub.kR.sup.14;
[0013] Y is N or CR.sup.15;
[0014] R.sup.1 is hydrogen, hydroxy, C.sub.1-5alkyl,
C.sub.1-5alkoxy-C.sub.1-5alkyl or hydroxy-C.sub.1-5alkyl;
[0015] R.sup.2 is hydrogen or C.sub.1-5alkyl;
[0016] R.sup.3 is hydrogen, cyano, C.sub.1-5alkyl,
C.sub.1-5alkoxy-C.sub.1-5alkyl or hydroxy-C.sub.1-5alkyl;
[0017] m is an integer selected from 0, 1, 2, 3, 4 and 5;
[0018] n is 0 or 1;
with the proviso that when X is --CO.sub.2R.sup.9 or
--CON(R.sup.10)R.sup.11, and n is 0, then m is an integer selected
from 1, 2, 3, 4 and 5;
[0019] R.sup.4 is hydrogen, hydroxy, hydroxy-C.sub.1-5alkyl, cyano,
cyano-C.sub.1-5alkyl or C.sub.1-5alkyl;
[0020] R.sup.5 is hydrogen or C.sub.1-5alkyl;
[0021] R.sup.6 is hydrogen, halogen, C.sub.1-5alkyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-5alkyl, hydroxy,
C.sub.1-5alkoxy, C.sub.3-8cycloalkyloxy or
--N(R.sup.16)R.sup.17;
[0022] R.sup.7 and R.sup.8 are the same or different, and
independently are hydrogen, halogen, C.sub.1-5alkyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-5alkyl, hydroxy,
C.sub.1-5alkoxy, C.sub.3-8cycloalkyloxy, --N(R.sup.18)R.sup.19,
--CO.sub.2R.sup.20, cyano, nitro, C.sub.1-5alkylthio,
trifluoromethyl or trifluoromethoxy; or R.sup.7 and R.sup.8 are
taken together to form --CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--
or --CH.dbd.CH--CH.dbd.CH--;
[0023] R.sup.9 is hydrogen, C.sub.1-20alkyl, aryl,
C.sub.3-8cycloalkyl or --CHR.sup.1aOC(.dbd.O)-A.sup.1-R.sup.1b,
wherein said C.sub.1-20alkyl optionally contains one to four double
bonds and/or one to four triple bonds, and/or said C.sub.1-20alkyl
is optionally substituted with one of the substituents selected
from the group consisting of hydroxy, halogen, cyano,
C.sub.1-10alkoxy, C.sub.1-5alkoxycarbonyl, C.sub.3-8cycloalkyl,
--C(.dbd.O)N(R.sup.2a)R.sup.2b, --N(R.sup.3a)R.sup.3b and aryl
which aryl is optionally substituted with one or more substituents,
which are the same or different, selected from the group consisting
of halogen, C.sub.1-5alkyl and C.sub.1-5alkoxy;
[0024] R.sup.1a is hydrogen or C.sub.1-5alkyl;
[0025] A.sup.1 is oxygen or a single bond;
[0026] R.sup.1b is C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0027] R.sup.2a and R.sup.2b are the same or different, and
independently hydrogen or C.sub.1-3alkyl;
[0028] R.sup.3a and R.sup.3b are the same or different, and
independently hydrogen or C.sub.1-3alky; or R.sup.3a and R.sup.3b
are taken together to form
--(CH.sub.2).sub.s-A.sup.2-(CH.sub.2).sub.t--;
[0029] A.sup.2 is methylene, oxygen, sulfur, NR.sup.4a or a single
bond;
[0030] R.sup.4a is hydrogen, C.sub.1-5alkyl or benzyl;
[0031] s and t are the same or different, and independently an
integer selected from 1, 2 or 3;
[0032] R.sup.11 is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0033] R.sup.11 is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-5alkyl or
--CHR.sup.5a--(CH.sub.2).sub.u--C(.dbd.O)R.sup.5b or R.sup.10 and
R.sup.11 are taken together to form
--(CH.sub.2).sub.v-A.sup.3-(CH.sub.2).sub.w--;
[0034] R.sup.5a is hydrogen, C.sub.1-5alkyl, aryl or heteroaryl,
wherein said C.sub.1-5alkyl is optionally substituted with one of
the substituents selected from the group consisting of aryl,
heteroaryl, hydroxy, hydroxycarbonyl, 4-hydroxyphenyl,
C.sub.1-5alkoxy, amino, guanidino, mercapto, C.sub.1-5alkylthio or
aminocarbonyl or R.sup.10 and R.sup.5a are taken together to form
--(CH.sub.2).sub.p--;
[0035] p is 3 or 4;
[0036] u is 0 or 1;
[0037] R.sup.5b is hydroxy, C.sub.1-5alkoxy, benzyloxy or
--N(R.sup.6a)R.sup.6b;
[0038] R.sup.6a and R.sup.6b are the same or different, and
independently hydrogen or C.sub.1-3 alkyl;
[0039] v and w are the same or different, and independently an
integer selected from 1, 2 or 3;
[0040] A.sup.3 is methylene, oxygen, sulfur or NR.sup.7a;
[0041] R.sup.7a is hydrogen, C.sub.1-5alkyl or benzyl;
[0042] R.sup.12 and R.sup.13 are the same or different, and
independently are --OR.sup.21 or --N(R.sup.22)R.sup.23;
[0043] R.sup.14 is --OR.sup.21 or --N(R.sup.22)R.sup.23;
[0044] k is 1 or 2;
[0045] R.sup.15 is hydrogen, C.sub.1-5alkyl, halogen, cyano or
--CO.sub.2R.sup.24;
[0046] R.sup.16 and R.sup.17 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5 alkyl;
[0047] R.sup.18 and R.sup.19 are the same or different, and
independently are hydrogen, C.sub.1-5 alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0048] R.sup.20 is hydrogen or C.sub.1-5alkyl;
[0049] R.sup.21 is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0050] R.sup.22 and R.sup.23 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5 alkyl;
[0051] R.sup.24 is hydrogen or C.sub.1-5alkyl;
[0052] Ar is aryl or heteroaryl which aryl or heteroaryl is
unsubstituted or substituted with one or more substituents, which
are the same or different, selected from the group consisting of
halogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl, C.sub.2-5alkenyl,
C.sub.2-5alkynyl, C.sub.1-5alkoxy, C.sub.1-5alkylthio,
C.sub.1-5alkylsulfinyl, cyano, nitro, hydroxy, --CO.sub.2R.sup.25,
--C(.dbd.O)R.sup.26, --CON(R.sup.27)R.sup.28, --OC(.dbd.O)R.sup.29,
--NR.sup.30CO.sub.2R.sup.31, --S(O).sub.rN(R.sup.32)R.sup.33,
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy,
methylenedioxy, ethylenedioxy and --N(R.sup.34)R.sup.35;
[0053] R.sup.25 is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0054] R.sup.26 is hydrogen or C.sub.1-5alkyl;
[0055] R.sup.27 and R.sup.28 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0056] R.sup.29 is hydrogen or C.sub.1-5alkyl;
[0057] R.sup.30 is hydrogen or C.sub.1-5alkyl;
[0058] R.sup.31 is hydrogen or C.sub.1-5alkyl;
[0059] R.sup.32 and R.sup.33 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0060] r is 1 or 2;
[0061] R.sup.34 and R.sup.35 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl), individual isomers thereof, or
racemic or non-racemic mixtures of isomers thereof or N-oxide
thereof, or pharmaceutically acceptable salts and hydrates
thereof.
[0062] The terms used in the present specification have the
following meanings.
[0063] The term "a 3- to 8-membered saturated cyclic amine" means
aziridine, azetidine, pyrrolidine, piperidine, azepane or
azocane.
[0064] The term "C.sub.1-5alkylene" means a straight or branched
chain alkylene of 1 to 5 carbon atoms, such as methylene, ethylene,
propylene, trimethylene, tetramethylene, pentamethylene or the
like.
[0065] The term "a 3- to 8-membered saturated cyclic amine bridged
with C.sub.1-5alkylene or C.sub.1-4alkylene-O--C.sub.1-4alkylene
between any different two carbon atoms of the cyclic amine"
includes, for example, 8-azabicyclo[3.2.1]oct-8-yl,
9-azabicyclo[3.3.1]non-9-yl, 7-azabicyclo[2.2.1]hept-7-yl,
3-oxa-7-azabicyclo[3.3.1]non-7-yl and
3-oxa-9-azabicyclo[3.3.1]non-9-yl.
[0066] The term "C.sub.1-20alkyl" means a straight chain or
branched chain alkyl group of 1 to 20 carbon atoms, such as methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, sec-butyl,
pentyl, isopentyl, tridecyl, 3,7,11,15-tetramethyl-hexadecyl or the
like.
[0067] The term "C.sub.1-20alkyl optionally contains one to four
double bonds and/or one to four triple bonds" includes for example,
allyl, 3,7-dimethyl-octa-2,6-dienyl, but-3-ynyl, dodec-11-ynyl or
the like.
[0068] The term "C.sub.1-10alkoxy" means a straight chain or
branched chain alkoxy group of 1 to 10 carbon atoms, such as
methoxy, ethoxy, propoxy, isopropyloxy, butoxy, isobutyloxy,
pentyloxy, isopentyloxy, decyloxy, 3,7-dimethyl-octyloxy or the
like.
[0069] The term "C.sub.1-5alkoxy-C.sub.1-5alkyl" means a
substituted C.sub.1-5alkyl group having the above-mentioned
C.sub.1-5alkoxy group as the substituent, such as methoxymethyl,
2-methoxyethyl, 2-ethoxyethyl or the like.
[0070] The term "hydroxy-C.sub.1-5alkyl" means a substituted
C.sub.1-5alkyl group having hydroxy group, such as hydroxymethyl,
1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl,
3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl or the like.
[0071] The term "cyano-C.sub.1-5alkyl" means a substituted
C.sub.1-5alkyl group having cyano group, such as cyanomethyl,
1-cyanoethyl, 2-cyanoethyl, 3-cyanopropyl, 4-cyanobutyl,
5-cyanopentyl or the like.
[0072] The term "C.sub.3-8cycloalkyl" means a cyclic alkyl group of
3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl or the like.
[0073] The term "C.sub.3-8cycloalkyl-C.sub.1-5alkyl" means a
substituted C.sub.1-5alkyl group having the above-mentioned
C.sub.3-8cycloalkyl as the substituent, such as cyclopropylmethyl,
cyclopropylethyl, cyclopentylethyl or the like.
[0074] The term "C.sub.3-8cycloalkyloxy" means a cyclic alkoxy
group of 3 to 8 carbon atoms, such as cyclopropyloxy,
cyclobutyloxy, cyclopentyloxy or the like.
[0075] The term "halogen" means fluorine, chlorine, bromine or
iodine atom.
[0076] The term "aryl" means a monocyclic or bicyclic group of 6 to
12 ring carbon atoms having at least one aromatic ring, such as
phenyl, naphthyl or the like.
[0077] The term "C.sub.1-5alkoxycarbonyl" means a carbonyl group
having above mentioned C.sub.1-5alkoxy group, such as
methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl or the like.
[0078] The term "heteroaryl" means a monocyclic or bicyclic group
of 5 to 12 ring atoms having at least one aromatic ring having in
its ring 1 to 4 atoms which may be the same or different and are
selected from nitrogen, oxygen and sulfur, such as pyridyl,
pyrimidinyl, imidazolyl, quinolyl, indolyl, benzofuranyl,
quinoxalinyl, benzo[1,2,5]thiadiazolyl, benzo[1,2,5]oxadiazolyl or
the like.
[0079] The term "C.sub.2-5alkenyl" means a straight chain or
branched chain alkenyl group of 2 to 5 carbon atoms, such as vinyl,
isopropenyl, allyl or the like.
[0080] The term "C.sub.2-5alkynyl" means a straight chain or
branched chain alkynyl group of 2 to 5 carbon atoms, such as
ethynyl, prop-1-ynyl, prop-2-ynyl or the like.
[0081] The term "C.sub.1-5alkylthio" means a straight chain or
branched chain alkylthio group of 1 to 5 carbon atoms, such as
methylthio, ethylthio, propylthio, isopropylthio or the like.
[0082] The term "C.sub.1-5alkysulfinyl" means a straight chain or
branched chain alkylsulfinyl group of 1 to 5 carbon atoms, such as
methanesulfinyl, ethanesulfinyl or the like.
[0083] The term "C.sub.1-5alkysulfonyl" means a straight chain or
branched chain alkylsulfonyl group of 1 to 5 carbon atoms, such as
methanesulfonyl, ethanesulfonyl or the like.
[0084] The term "aryl or heteroaryl which aryl or heteroaryl is
unsubstituted or substituted with one or more substituents, which
are the same or different, selected from the group consisting of
halogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl, C.sub.2-5alkenyl,
C.sub.2-5alkynyl, C.sub.1-5alkoxy, C.sub.1-5alkylthio,
C.sub.1-5alkylsulfinyl, C.sub.1-5alkylsulfonyl, cyano, nitro,
hydroxy, --CO.sub.2R.sup.25, --C(.dbd.O)R.sup.26,
--CON(R.sup.27)R.sup.28, --OC(.dbd.O)R.sup.29,
--NR.sup.30CO.sub.2R.sup.31, --S(O).sub.rN(R.sup.32)R.sup.33,
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy,
methylenedioxy, ethylenedioxy and --N(R.sup.34)R.sup.35" includes
for example, 2,4-dimethylphenyl, 2,6-dimethylphenyl,
2,4-dibromophenyl, 2-bromo-4-isoproylphenyl, 2,4-dichlorophenyl,
2,6-dichlorophenyl, 2-chloro-4-trifluoromethylphenyl,
4-methoxy-2-methylphenyl, 2-chloro-4-trifluoromethoxyphenyl,
4-isopropyl-2-methylthiophenyl, 2,4,6-trimethylphenyl,
4-bromo-2,6-dimethylphenyl, 4-bromo-2,6-diethylphenyl,
4-chloro-2,6-dimethylphenyl, 2,4,6-tribromophenyl,
2,4,5-tribromophenyl, 2,4,6-trichlorophenyl, 2,4,5-trichlorophenyl,
4-bromo-2,6-dichlorophenyl, 6-chloro-2,4-dibromophenyl,
2,4-dibromo-6-fluorophenyl, 2,4-dibromo-6-methylphenyl,
2,4-dibromo-6-methoxyphenyl, 2,4-dibromo-6-methylthiophenyl,
2,6-dibromo-4-isopropylphenyl, 2,6-dibromo-4-trifluoromethylphenyl,
2-bromo-4-trifluoromethylphenyl, 4-bromo-2-chlorophenyl,
2-bromo-4-chlorophenyl, 4-bromo-2-methylphenyl,
4-chloro-2-methylphenyl, 2,4-dimethoxyphenyl,
2,6-dimethyl-4-methoxyphenyl, 4-chloro-2,6-dibromophenyl,
4-bromo-2,6-difluorophenyl, 2,6-dichloro-4-trifluoromethylphenyl,
2,6-dichloro-4-trifluoromethoxyphenyl,
2,6-dibromo-4-trifluoromethoxyphenyl, 2-chloro-4,6-dimethylphenyl,
2-bromo-4,6-dimethoxyphenyl, 2-bromo-4-isopropyl-6-methoxyphenyl,
2,4-dimethoxy-6-methylphenyl, 6-dimethylamino-4-methylpyridin-3-yl,
2-chloro-6-trifluoromethylpyridin-3-yl,
2-chloro-6-trifluoromethoxypyridin-3-yl,
2-chloro-6-methoxypyridin-3-yl,
6-methoxy-2-trifluoromethylpyridin-3-yl,
2-chloro-6-difluoromethylpyridin-3-yl,
6-methoxy-2-methylpyridin-3-yl, 2,6-dimethoxypyridin-3-yl,
4,6-dimethyl-2-trifluoromethylpyrimidin-5-yl,
2-dimethylamino-6-methylpyridin-3-yl,
6-dimethylamino-2-methylpyridin-3-yl,
2,3-dihydrobenzo[1,4]dioxin-5-yl and benzo[1,3]dioxol-4-yl,
5,7-dimethylbenzo[1,2,5]thiadiazol-4-yl,
5,7-dimethylbenzo[1,2,5]oxadiazol-4-yl,
2-isopropoxy-6-trifluoromethylpyridin-3-yl,
2-methoxy-6-methylpyridin-3-yl, 2,6-dimethylpyridin-3-yl,
2-bromo-6-methoxypyridin-3-yl,
2-chloro-6-dimethylaminopyridin-3-yl, 2,6-dichloropyridin-3-yl,
2,4-dimethyl-6-dimethylaminopyridin-3-yl,
2,4,6-trimethylpyridin-3-yl, 2,4,6-trimethylpyrimidin-5-yl,
4,6-dimethyl-2-dimethylaminopyrimidin-5-yl,
5-iodo-3-methylpyridin-2-yl, 3-methyl-5-methylaminopyridin-2-yl,
3-dimethylamino-5-methylpyridin-2-yl,
5-methyl-3-methylaminopyridin-2-yl, 3-chloro-5-methylpyridin-2-yl,
3-amino-5-methylpyridin-2-yl, 5-methyl-3-nitropyridin-2-yl,
5-diethylamino-3-methylpyridin-2-yl, 5-fluoro-3-methylpyridin-2-yl,
5-chloro-3-methylpyridin-2-yl,
5-dimethylamino-3-methylpyridin-2-yl, 5-amino-3-methylpyridin-2-yl,
3-methyl-5-nitropyridin-2-yl, 3-bromo-5-methylpyridin-2-yl,
4-chloro-2,5-dimethoxyphenyl, 4,5-dimethyl-2-methoxyphenyl,
5-fluoro-2,4-dimethylphenyl, 2,4-dimethoxy-5-methylphenyl,
2-chloro-4-methoxy-5-methylphenyl,
2-chloro-5-fluoro-4-methylphenyl, 2-bromo-4,5-dimethoxyphenyl,
2-bromo-5-fluoro-4-methoxyphenyl, 2-chloro-4,5-dimethoxyphenyl,
2.5-dichloro-4-methoxyphenyl, 2,4-dichloro-5-fluorophenyl,
2-chloro-5-fluoro-4-methoxyphenyl, 2,4,5-trichlorophenyl,
2-chloro-5-fluoro-4-methylphenyl,
5-fluoro-4-methoxy-2-methylphenyl, 4,5-dimethoxy-2-methylphenyl,
5-chloro-4-methoxy-2-methylphenyl, 2,4,5-trimethylphenyl,
6-methoxy-4-methylpyridin-3-yl, 4-methoxy-6-methylpyridin-3-yl,
4,6-dimethylpyridin-3-yl, 2-chloro-4-isopropylphenyl,
2-chloro-4-methylphenyl, 4-amino-2-chlorophenyl,
2-chloro-4-dimethylcarbamoylphenyl,
2-chloro-4-methylcarbamoylphenyl, 4-carbamoyl-2-chlorophenyl,
2-chloro-4-methylsulfonylphenyl, 4-carboxy-2-chlorophenyl,
2-chloro-4-iodophenyl, 2-bromo-4-methylthiophenyl,
2-bromo-4-methylsulfinylphenyl, 2-bromo-4-dimethylaminophenyl,
2-bromo-4-methylsulfonylphenyl, 2-bromo-4-cyclopentylphenyl,
2-bromo-4-tert-butylphenyl, 2-bromo-4-propylphenyl,
2-bromo-4-methylphenyl, 2-bromo-4-trifluoromethoxyphenyl,
2-bromo-4-methoxyphenyl, 2-bromo-4-ethoxyphenyl,
4-isopropyl-2-methylsulfonylphenyl,
4-cyclopentyl-2-methylthiophenyl, 4-butyl-2-methylthiophenyl,
4-methoxy-2-methylthiophenyl, 2-methylthio-4-propylphenyl,
2-dimethylamino-4-isopropylphenyl, 2-iodo-4-isopropylphenyl,
2-fluoro-4-methylphenyl, 2,4-difluorophenyl,
2-chloro-4-methoxyphenyl, 2-chloro-4-hydroxyphenyl,
4-cyano-2-methoxyphenyl, 4-bromo-2-methoxyphenyl,
2-methoxy-4-methylphenyl, 4-chloro-2-methoxyphenyl,
2-hydroxy-4-methylphenyl, 4-fluoro-2-methoxyphenyl,
2-hydroxy-4-methylphenyl, 4-cyano-2-methoxyphenyl,
2-chloro-4-methylthiophenyl, 2-methoxy-4-trifluoromethylphenyl,
4-isopropyl-2-methoxyphenyl, 2-chloro-4-cyanophenyl,
2-chloro-4-ethoxycarbonylphenyl, 2-chloro-4-methylaminophenyl,
4-cyano-2-trifluoromethylphenyl, 4-cyano-2-methylphenyl,
2-methyl-4-trifluoromethoxyphenyl, 2-cyano-4-trifluoromethylphenyl,
4-carboxyamino-2-trifluoromethylphenyl,
4-methoxy-2-trifluoromethylphenyl, 4-fluoro-2-methylphenyl,
4-hydroxy-2-methylphenyl, 4-methoxy-2-methoxycarbonylphenyl,
2-ethyl-4-methoxyphenyl, 2-formyl-4-methoxyphenyl,
4-chloro-2-trifluoromethylphenyl,
4-dimethylamino-2-trifluoromethylphenyl,
4-difluoromethoxy-2-methylphenyl, 2-cyano-4-methoxyphenyl,
4-hydroxy-2-trifluoromethylphenyl,
4-isopropyl-2-trifluoromethylphenyl, 4-diethylamino-2-methylphenyl,
4-fluoro-2-trifluoromethylphenyl,
4-propoxy-2-trifluoromethylphenyl,
4-dimethylamino-2-methylthiophenyl,
4-isopropyl-2-isopropylthiophenyl, 2-ethylthio-4-isopropylphenyl,
4-methylamino-2-methylthiophenyl, 2-methylthio-4-propionylphenyl,
4-acetyl-2-methylthiophenyl, 4-cyano-2-methylthiophenyl,
4-methoxy-2-methylthiophenyl, 4-ethyl-2-methylthiophenyl,
4-bromo-2-methylthiophenyl, 4-isopropyl-2-methylsulfinylphenyl,
2,4-dimethylthiophenyl, 4,6-dimethyl-2-isopropylphenyl,
4,6-dimethyl-2-isopropenylphenyl, 2-acetyl-4,6-dimethylphenyl,
2,6-dimethyl-4-trifluoromethylphenyl,
2,6-dimethyl-4-isopropenylphenyl, 4-acetyl-2,6-dimethylphenyl,
2,4,6-triethylphenyl, 4,6-dimethyl-2-methylthiophenyl,
4,6-dimethyl-2-iodophenyl, 2-fluoromethoxy-4,6-dimethylphenyl,
4,6-dimethyl-2-isopropoxyphenyl, 4,6-dimethyl-2-ethoxyphenyl,
2,6-dichloro-4-ethoxyphenyl, 2-bromo-4,6-dimethoxyphenyl,
2-bromo-6-hydroxy-4-methoxyphenyl, 2,6-dibromo-4-ethoxyphenyl,
4-bromo-2-methoxy-6-methylphenyl, 2,6-dibromo-4-methoxyphenyl,
4,6-dibromo-2-trifluoromethoxyphenyl,
2,4-dibromo-6-trifluoromethylphenyl,
4-bromo-2-chloro-6-methylphenyl, 4-chloro-2,6-dimethoxyphenyl,
2,4-dichloro-6-methoxyphenyl, 4,6-dichloro-2-methylthiophenyl,
4,6-dichloro-2-trifluoromethylphenyl, 2,6-dimethoxy-4-ethylphenyl,
4,6-dimethyl-2-methoxyphenyl, 2,6-dimethoxy-4-methylphenyl,
2-chloro-6-methoxy-4-methylphenyl, 4,6-dimethyl-2-ethoxyphenyl,
6-hydroxy-2,4-dimethylphenyl, 4-cyano-2-methoxy-6-methylphenyl,
6-fluoro-2-methoxy-4-methylphenyl,
4-acetyl-2-methoxy-6-methylphenyl, 2-chloro-4,6-dimethoxyphenyl,
2,6-dimethoxy-4-ethoxyphenyl, 2,4,6-trimethoxyphenyl,
4,6-dibromo-2-trifluoromethoxyphenyl,
2-bromo-4-dimethylamino-6-methoxyphenyl,
4-bromo-2-methoxy-6-methylphenyl, 4,6-dimethoxy-2-propoxyphenyl,
4,6-dichloro-2-propoxyphenyl, 2-bromo-6-hydroxy-4-methoxyphenyl,
2,4,6-trifluorophenyl, 2-bromo-6-fluoro-4-methylphenyl,
4-difluoromethoxy-2,6-dimethylphenyl, 2,6-dimethyl-4-ethoxyphenyl,
2,6-dimethyl-4-isopropoxyphenyl, 2,6-dimethyl-4-methylthiophenyl,
2,6-dimethyl-4-methylsulfonylophenyl,
2,6-dimethyl-4-methylsulfinylophenyl, 2,3-dichlorophenyl,
4-methoxy-2,3-dimethylphenyl, 2-chloro-3-fluoro-4-methoxyphenyl,
2,3,4-trichlorophenyl, 4-methoxy-2,5-dimethylphenyl,
4-cyano-2,6-dimethylphenyl and 4-fluoro-2,6-dimethylphenyl.
[0085] The "pharmaceutically acceptable salts" in the present
invention include, for example, salts with an inorganic acid such
as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric
acid, nitric acid or the like; salts with an organic acid such as
acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid,
maleic acid, citric acid, benzenesulfonic acid, methanesulfonic
acid, p-toluenesulfonic acid, benzoic acid, camphorsulfonic acid,
ethanesulfonic acid, glucoheptonic acid, gluconic acid, glutamic
acid, glycolic acid, malic acid, malonic acid, mandelic acid,
galactaric acid, naphthalene-2-sulfonic acid or the like; salts
with one or more metal ions such as lithium ion, sodium ion,
potassium ion, calcium ion, magnesium ion, zinc ion, aluminium ion
or the like; salts with amines such as ammonia, arginine, lysine,
piperazine, choline, diethylamine, 4-phenylcyclohexylamine,
2-aminoethanol, benzathine or the like.
[0086] A compound of the present invention includes any isomers
such as diastereomers, enantiomers, geometric isomers and
tautomeric forms. In a compound represented by formula [I], if the
cyclic amino group has one or more chiral carbons and/or if there
is an axial chirality between Ar and pyrrolopyrimidine (or
pyrrolopyridine) ring, several stereoisomers (diastereomers or
enantiomers) can exist. The compound of the present invention
includes all of the individual isomers and the racemic and
non-racemic mixtures of the isomers.
[0087] Preferable examples of the compound of the present invention
are as follows.
[0088] That is, preferable are compounds represented by the
following formula [I]:
##STR00004##
(wherein the cyclic amino group is represented by the following
formula [II]:
##STR00005##
[0089] in which the cyclic amino group is a 3- to 8-membered
saturated cyclic amine or a 3- to 8-membered saturated cyclic amine
bridged with C.sub.1-5alkylene or
C.sub.1-4alkylene-O--C.sub.1-4alkylene between any different two
carbon atoms of the cyclic amine, which cyclic amine is substituted
with a group represented by
--(CR.sup.1R.sup.2).sub.m--(CHR.sup.3).sub.n--X, R.sup.4 and
R.sup.5 independently on the same or different carbon atoms of the
cyclic amine;
[0090] X is --CO.sub.2R.sup.9, --CON(R.sup.10)R.sup.11,
--P(.dbd.O)(R.sup.12)R.sup.13 or --S(.dbd.O).sub.kR.sub.14;
[0091] Y is N or CR.sup.15;
[0092] R.sup.1 is hydrogen, hydroxy, C.sub.1-5alkyl,
C.sub.1-5alkoxy-C.sub.1-5alkyl or hydroxy-C.sub.1-5alkyl;
[0093] R.sup.2 is hydrogen or C.sub.1-5alkyl;
[0094] R.sup.3 is hydrogen, cyano, C.sub.1-5alkyl,
C.sub.1-5alkoxy-C.sub.1-5alkyl or hydroxy-C.sub.1-5alkyl;
[0095] m is an integer selected from 0, 1, 2, 3, 4 and 5;
[0096] n is 0 or 1;
[0097] with the proviso that when X is --CO.sub.2R.sup.9 or
--CON(R.sup.10)R.sup.11, and n is 0, then m is an integer selected
from 1, 2, 3, 4 and 5;
[0098] R.sup.4 is hydrogen, hydroxy, hydroxy-C.sub.1-5alkyl, cyano,
cyano-C.sub.1-5alkyl or C.sub.1-5alkyl;
[0099] R.sup.5 is hydrogen or C.sub.1-5alkyl;
[0100] R.sup.6 is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-5alkyl, hydroxy, C.sub.1-5alkoxy,
C.sub.3-8cycloalkyloxy or --N(R.sup.16)R.sup.17;
[0101] R.sup.7 and R.sup.8 are the same or different, and
independently are hydrogen, halogen, C.sub.1-5 alkyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-5alkyl, hydroxy,
C.sub.1-5alkoxy, C.sub.3-8cycloalkyloxy, --N(R.sup.18)R.sup.19,
--CO.sub.2R.sup.20, cyano, nitro, C.sub.1-5alkylthio,
trifluoromethyl or trifluoromethoxy; or R.sup.7 and R.sup.8 are
taken together to form --CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--
or --CH.dbd.CH--CH.dbd.CH--;
[0102] R.sup.9 is hydrogen, C.sub.1-10alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0103] R.sup.10 and R.sup.11 are the same or different, and
independently are hydrogen, C.sub.1-5 alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0104] R.sup.12 and R.sup.13 are the same or different, and
independently are --OR.sup.21 or --N(R.sup.22)R.sup.23;
[0105] R.sup.14 is --OR.sup.21 or --N(R.sup.22)R.sup.23;
[0106] k is 1 or 2;
[0107] R.sup.15 is hydrogen, C.sub.1-5alkyl, halogen, cyano or
--CO.sub.2R.sup.24;
[0108] R.sup.16 and R.sup.17 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0109] R.sup.18 and R.sup.19 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0110] R.sup.20 is hydrogen or C.sub.1-5alkyl;
[0111] R.sup.21 is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0112] R.sup.22 and R.sup.23 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0113] R.sup.24 is hydrogen or C.sub.1-5alkyl;
[0114] Ar is aryl or heteroaryl which aryl or heteroaryl is
unsubstituted or substituted with 1 or more substituents, which are
the same or different, selected from the group consisting of
halogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl, C.sub.2-5alkenyl,
C.sub.2-5alkynyl, C.sub.1-5alkoxy, C.sub.1-5alkylthio,
C.sub.1-5alkylsulfonyl, cyano, nitro, hydroxy, --CO.sub.2R.sup.25,
--C(.dbd.O)R.sup.26, --CON(R.sup.27) R.sup.28,
--OC(.dbd.O)R.sup.29, --NR.sup.30CO.sub.2R.sup.31,
--S(O).sub.rN(R.sup.32)R.sup.33, trifluoromethyl, trifluoromethoxy,
difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and
--N(R.sup.34)R.sup.35;
[0115] R.sup.25 is hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0116] R.sup.26 is hydrogen or C.sub.1-5alkyl;
[0117] R.sup.27 and R.sup.28 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0118] R.sup.29 is hydrogen or C.sub.1-5alkyl;
[0119] R.sup.30 is hydrogen or C.sub.1-5alkyl;
[0120] R.sup.31 is hydrogen or C.sub.1-5alkyl;
[0121] R.sup.32 and R.sup.33 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl;
[0122] r is 1 or 2;
[0123] R.sup.34 and R.sup.35 are the same or different, and
independently are hydrogen, C.sub.1-5alkyl, C.sub.3-8cycloalkyl or
C.sub.3-8cycloalkyl-C.sub.1-5alkyl), individual isomers thereof,
racemic or non-racemic mixtures of isomers thereof or N-oxide
thereof, or pharmaceutically acceptable salts and hydrates
thereof.
[0124] More preferable are compounds represented by the formula [I]
in which Y is N. More preferable are compounds represented by the
formula [I] in which Y is N; m is an integer selected from 1, 2, 3,
4 and 5; n is 0; R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are
hydrogen. More preferable are compounds represented by the formula
[I] in which Y is N; the cyclic amino group is a 4- to 7-membered
saturated cyclic amine; m is an integer selected from 1, 2 and 3; n
is 0; R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are hydrogen; R.sup.6
is C.sub.1-5alkyl; R.sup.7 and R.sup.8 are the same or different,
and independently are hydrogen or C.sub.1-5alkyl; Ar is phenyl
which phenyl is substituted with two or three substituents, which
are the same or different, selected from the group consisting of
halogen, C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkylthio,
trifluoromethyl, trifluoromethoxy and --N(R.sup.34)R.sup.35
(wherein R.sup.34 and R.sup.35 are the same or different, and
independently are hydrogen or C.sub.1-3alkyl). More preferable are
compounds represented by the formula [I] in which X is --CO.sub.2H,
--CONH.sub.2, --P(.dbd.O)(OH).sub.2 or --S(.dbd.O).sub.2OH; Y is N;
the cyclic amino group is a 6-membered saturated cyclic amine; m is
an integer selected from 1, 2 and 3; n is 0; R.sup.1, R.sup.2,
R.sup.4 and R.sup.5 are hydrogen; R.sup.6 is C.sub.1-3alkyl;
R.sup.7 and R.sup.8 are the same or different, and independently
are hydrogen or C.sub.1-3alkyl; Ar is phenyl which phenyl is
substituted with two or three substituents, which are the same or
different, selected from the group consisting of chloro, bromo,
C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkylthio,
trifluoromethyl, trifluoromethoxy and dimethylamino. More
preferable are compounds represented by the formula [I] in which X
is --CO.sub.2H; Y is N; the cyclic amino group is a 6-membered
saturated cyclic amine; m is an integer selected from 1, 2 and 3; n
is 0; R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are hydrogen; R.sup.6
is methyl; R.sup.7 and R.sup.8 are the same or different, and
independently are hydrogen or methyl; Ar is phenyl which phenyl is
substituted with two or three substituents, which are the same or
different, selected from the group consisting of chloro, bromo,
C.sub.1-3 alkyl, C.sub.1-3 alkoxy, C.sub.1-3 alkylthio and
trifluoromethyl.
[0125] Other preferable are compounds represented by the formula
[I] in which Y is CR.sup.15. More preferable are compounds
represented by the formula [I] in which Y is CR.sup.15; m is an
integer selected from 1, 2, 3, 4 and 5; n is 0; R.sup.1, R.sup.2,
R.sup.4 and R.sup.5 are hydrogen; R.sup.15 is hydrogen or halogen.
More preferable are compounds represented by the formula [I] in
which Y is CH; the cyclic amino group is a 4- to 7-membered
saturated cyclic amine; m is an integer selected from 1, 2 and 3; n
is 0; R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are hydrogen; R.sup.6
is C.sub.1-5alkyl; R.sup.7 and R.sup.8 are the same or different,
and independently are hydrogen or C.sub.1-5alkyl; Ar is phenyl
which phenyl is substituted with two or three substituents, which
are the same or different, selected from the group consisting of
halogen, C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkylthio,
trifluoromethyl, trifluoromethoxy and --N(R.sup.34)R.sup.35
(wherein R.sup.34 and R.sup.35 are the same or different, and
independently are hydrogen or C.sub.1-3alkyl. More preferable are
compounds represented by the formula [I] in which X is --CO.sub.2H,
--CONH.sub.2, --P(.dbd.O)(OH).sub.2 or --S(.dbd.O).sub.2OH; Y is
CH; the cyclic amino group is a 6-membered saturated cyclic amine;
m is an integer selected from 1, 2 and 3; n is 0; R.sup.1, R.sup.2,
R.sup.4 and R.sup.5 are hydrogen; R.sup.6 is C.sub.1-3alkyl;
R.sup.7 and R.sup.8 are the same or different, and independently
are hydrogen or C.sub.1-3alkyl; Ar is phenyl which phenyl is
substituted with two or three substituents, which are the same or
different, selected from the group consisting of chloro, bromo,
C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkylthio,
trifluoromethyl, trifluoromethoxy and dimethylamino. More
preferable are compounds represented by the formula [I] in which X
is --CO.sub.2H; Y is CH; the cyclic amino group is a 6-membered
saturated cyclic amine; m is an integer selected from 1, 2 and 3; n
is 0; R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are hydrogen; R.sup.6
is methyl; R.sup.7 and R.sup.8 are the same or different, and
independently are hydrogen or methyl; Ar is phenyl which phenyl is
substituted with two or three substituents, which are the same or
different, selected from the group consisting of chloro, bromo,
C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkylthio and
trifluoromethyl.
[0126] The preferable cyclic amino group is 6-membered saturated
amine.
[0127] The preferable X is CO.sub.2H, CONH.sub.2, P(O)(OH).sub.2 or
S(O).sub.2OH. The more preferable X is CO.sub.2H.
[0128] The preferable Y is N or CH.
[0129] The preferable R.sup.1 is hydrogen.
[0130] The preferable R.sup.2 is hydrogen.
[0131] The preferable R.sup.3 is hydrogen.
[0132] The preferable R.sup.4 is hydrogen.
[0133] The preferable R.sup.5 is hydrogen.
[0134] The preferable R.sup.6 is C.sub.1-3 alkyl. The more
preferable R.sup.6 is methyl.
[0135] The preferable R.sup.7 is C.sub.1-3 alkyl. The more
preferable R.sup.7 is methyl.
[0136] The preferable R.sup.8 is hydrogen or C.sub.1-3 alkyl. The
more preferable R.sup.8 is hydrogen or methyl.
[0137] The preferable Ar is phenyl which phenyl is substituted with
two or three substituents, which are the same or different,
selected from the group consisting of chloro, bromo,
C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkylthio,
trifluoromethyl, trifluoromethoxy and dimethylamino. The more
preferable Ar is phenyl which phenyl is substituted with two or
three substituents, which are the same or different, selected from
the group consisting of chloro, bromo and C.sub.1-3alkyl.
[0138] Especially preferable compounds of the present invention
are: [0139]
{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-
-d]pyrimidin-4-yl]-piperidin-4-yl}-acetic acid
[0139] ##STR00006## [0140] ,
{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimid-
in-4-yl]-piperidin-4-yl}-acetic acid
[0140] ##STR00007## [0141] ,
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]pyri-
din-4-yl]-piperidin-4-yl}-acetic acid
[0141] ##STR00008## [0142] ,
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid
[0142] ##STR00009## [0143] ,
{1-[1-(4-chloro-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]pyr-
idin-4-yl]-piperidin-4-yl}-acetic acid
[0143] ##STR00010## [0144] ,
{1-[1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridi-
n-4-yl]-piperidin-4-yl}-acetic acid
[0144] ##STR00011## [0145] ,
{1-[1-(2,6-dibromo-4-isopropyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]p-
yridin-4-yl]-piperidin-4-yl}-acetic acid
[0145] ##STR00012## [0146] ,
{1-[1-(2,6-dibromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyri-
din-4-yl]-piperidin-4-yl}-acetic acid
[0146] ##STR00013## [0147] ,
{1-[3,6-dimethyl-1-(2,4,6-tribromo-phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-
-piperidin-4-yl}-acetic acid
[0147] ##STR00014## [0148] ,
{1-[1-(4-bromo-2,6-dichloro-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid
[0148] ##STR00015## [0149] ,
{1-[3,6-dimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl-
]-piperidin-4-yl}-acetic acid
[0149] ##STR00016## [0150] ,
{1-[1-(2,6-dibromo-4-chloro-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid
[0150] ##STR00017## [0151] ,
{1-[1-(2-bromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin--
4-yl]-piperidin-4-yl}-acetic acid
[0151] ##STR00018## [0152] ,
{1-[1-(4-isopropyl-2-methylsulfanyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b-
]pyridin-4-yl]-piperidin-4-yl}-acetic acid
[0152] ##STR00019## [0153] ,
{1-[1-(2,4-dibromo-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-pi-
peridin-4-yl}-acetic acid
[0153] ##STR00020## [0154] ,
3-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-piperidin-4-yl}-propionic acid
[0154] ##STR00021## [0155] ,
3-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrim-
idin-4-yl]-piperidin-4-yl}-propionic acid
[0155] ##STR00022## [0156] ,
3-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]py-
ridin-4-yl]-piperidin-4-yl}-propionic acid
[0156] ##STR00023## [0157] ,
3-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-propionic acid
[0157] ##STR00024## [0158] ,
3-{1-[1-(4-chloro-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]p-
yridin-4-yl]-piperidin-4-yl}-propionic acid
[0158] ##STR00025## [0159] ,
3-{1-[1-(4-chloro-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyri-
din-4-yl]-piperidin-4-yl}-propionic acid
[0159] ##STR00026## [0160] ,
3-{1-[1-(2,6-dibromo-4-isopropyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b-
]pyridin-4-yl]-piperidin-4-yl}propionic acid
[0160] ##STR00027## [0161] ,
3-{1-[1-(2,6-dibromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]py-
ridin-4-yl]-piperidin-4-yl}-propionic acid
[0161] ##STR00028## [0162] ,
3-{1-[1-(4-bromo-2,6-dichloro-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-propionic acid
[0162] ##STR00029## [0163] ,
3-{1-[3,6-dimethyl-1-(2,4,6-trichloro-phenyl)-1H-pyrrolo[2,3-b]pyridin-4--
yl]-piperidin-4-yl}-propionic acid
[0163] ##STR00030## [0164] ,
3-{1-[1-(2,6-dibromo-4-chloro-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-propionic acid
[0164] ##STR00031## [0165] ,
3-{1-[1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyr-
idin-4-yl]-piperidin-4-yl}-propionic acid
[0165] ##STR00032## [0166] ,
3-{1-[1-(2-bromo-4-isopropyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridi-
n-4-yl]-piperidin-4-yl}-propionic acid
[0166] ##STR00033## [0167] ,
3-{1-[1-(4-isopropyl-2-methylsulfanyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-
-b]pyridin-4-yl]-piperidin-4-yl}-propionic acid
[0167] ##STR00034## [0168] ,
3-{1-[1-(2,4-dibromo-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]--
piperidin-4-yl}-propionic acid
[0168] ##STR00035## [0169] ,
4-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-2,3,6-trimethyl-1H-pyrrolo[2,3-b]py-
ridin-4-yl]-piperidin-4-yl}-butyric acid
[0169] ##STR00036## [0170] ,
4-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-butyric acid
[0170] ##STR00037## [0171] ,
{8-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-8-aza-bicyclo[3.2.1]oct-3-yl}-acetic acid
[0171] ##STR00038## [0172] ,
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-3-yl}-acetic acid
[0172] ##STR00039## [0173] ,
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-acetamide
[0173] ##STR00040## [0174] ,
3-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-propionamide
[0174] ##STR00041## [0175] ,
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-ylmethyl}-phosphonic acid
[0175] ##STR00042## [0176] ,
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-methanesulfonic acid
[0176] ##STR00043## [0177] ,
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-ethanesulfonic acid
[0177] ##STR00044## [0178] ,
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-ethanesulfonic acid amide
[0178] ##STR00045## [0179] ,
{1-[7-(4-isopropyl-2-methylsulfanyl-phenyl)-2,5-dimethyl-7H-pyrrolo[2,3-d-
]pyrimidin-4-yl]-piperidin-4-yl}-acetic acid
[0179] ##STR00046## [0180] ,
4-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-piperidin-4-yl}-butyric acid
[0180] ##STR00047## [0181] ,
2-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-3,3-dimethyl-piperidin-4-yl}-acetamide
[0181] ##STR00048## [0182] , 2,2-dimethyl-propionic acid
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-acetoxymethyl ester
[0182] ##STR00049## [0183] , and
(S)-2-(2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3--
b]pyridin-4-yl]-piperidin-4-yl}-acetylamino)-3-phenyl-propionic
acid ethyl ester.
##STR00050##
[0184] The compound represented by the formula [I] can be produced,
for example, by the process shown in the following reaction schemes
1-4 [in the following reaction scheme, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8; m, n, Y and Ar are as
defined above; L.sup.1, L.sup.2 and L.sup.3 are the same or
different, and independently chloro, bromo, iodo,
methanesulfonyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy or
trifluoromethanesulfonyloxy group; X.sup.a is --CN,
--CO.sub.2(C.sub.1-5alkyl), --CON(R.sup.10)R.sup.11 or
--S(O).sub.2N(R.sup.22)R.sup.23; X.sup.b is OR.sup.9 or
N(R.sup.10)R.sup.11; R.sup.aK is C.sub.1-5alkyl; d is an integer
selected from 1, 2, 3, 4, 5 and 6; e and f are the same or
different, independently, integers selected from 1, 2 and 3].
##STR00051##
Step 1:
[0185] Compound (3), a compound of the present invention, can be
obtained by reacting Compound (1) with Compound (2) in an inert
solvent or without any solvent in the presence or absence of a
base. Herein, the base includes, for example, amines such as
triethylamine, N,N-diisopropylethylamine, pyridine and the like;
inorganic bases such as sodium carbonate, potassium carbonate,
sodium hydrogencarbonate, potassium hydrogencarbonate, sodium
hydroxide, potassium hydroxide, barium hydroxide, sodium hydride
and the like; metal alcoholates such as sodium methoxide, sodium
ethoxide, potassium tert-butoxide and the like; metal amides such
as sodium amide, lithium diisopropylamide and the like; and
Grignard reagents such as methylmagnesium bromide and the like. The
inert solvent includes, for example, alcohols such as methanol,
ethanol, isopropyl alcohol, ethylene glycol and the like; ethers
such as diethyl ether, tetrahydrofuran, 1,4-dioxane,
1,2-dimethoxyethane and the like; hydrocarbons such as benzene,
toluene, xylene and the like; esters such as ethyl acetate, ethyl
formate and the like; amides such as N,N-dimethylformamide,
N-methylpyrrolidone, N,N-dimethylacetamide and the like;
acetonitrile; dimethyl sulfoxide; pyridine; chloroform;
dichloromethane; water; and mixtures of solvents selected from
these inert solvents.
Step 2:
[0186] When X.sup.a is a cyano group, the cyano group can be
converted to the carboxy group, a C.sub.1-5alkoxycarbonyl group or
the carbamoyl group by using an acid or a base in an inert solvent
or without any solvent. Herein, the acid includes, for example,
organic acids such as formic acid, acetic acid, trifluoroacetic
acid, benzenesulfonic acid, methanesulfonic acid, p-toluenesulfonic
acid, benzoic acid, trifluoromethanesulfonic acid and the like;
inorganic acids such as sulfuric acid, hydrochloric acid,
hydrobromic acid, phosphoric acid, polyphosphoric acid, nitric acid
or the like. The base includes, for example, inorganic bases such
as sodium carbonate, potassium carbonate, sodium hydrogencarbonate,
potassium hydrogencarbonate, sodium hydroxide, potassium hydroxide,
lithium hydroxide, barium hydroxide and the like; metal alcoholates
such as sodium methoxide, sodium ethoxide, potassium tert-butoxide
and the like. The inert solvent includes, for example, alcohols
such as methanol, ethanol, isopropyl alcohol, ethylene glycol,
tert-butanol and the like; ethers such as diethyl ether,
tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like;
hydrocarbons such as benzene, toluene, xylene and the like; esters
such as ethyl acetate, ethyl formate and the like; amides such as
N,N-dimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide
and the like; acetonitrile; dimethyl sulfoxide; pyridine;
chloroform; dichloromethane; water; and mixtures of solvents
selected from these inert solvents.
##STR00052##
Step 3:
[0187] The hydroxy group in Compound (5), which can be prepared in
the similar method as described in step 1, can be converted to
L.sup.2 by using a halogenating agent or a sulfonating agent in the
presence or absence of a base in an inert solvent or without any
solvent. Herein, the halogenating reagent includes, for example,
phosphoryl chloride, phosphoryl bromide, phosphorous pentachloride,
phosphorous trichloride, phosphorous pentabromide, phosphorous
tribromide, thionyl chloride, thionyl bromide, oxalyl chloride,
oxalyl bromide, PPh.sub.3-CCl.sub.4, PPh.sub.3-CBr.sub.4 and the
like. The sulfonating reagent includes, for example,
p-toluenesulfonyl chloride, methanesulfonyl chloride,
p-toluenesulfonic anhydride, methansulfonic anhydride,
trifluoromethanesulfonic anhydride,
N-phenylbis(trifluoromethanesulfonimide) and the like. The base
includes, for example, amines such as triethylamine,
N,N-diisopropylethylamine, pyridine, N,N-dimethylaniline,
N,N-diethylaniline and the like; inorganic bases such as sodium
carbonate, potassium carbonate, sodium hydrogencarbonate, potassium
hydrogencarbonate, sodium hydroxide, potassium hydroxide, barium
hydroxide, sodium hydride and the like; metal alcoholates such as
sodium methoxide, sodium ethoxide, potassium tert-butoxide and the
like; metal amides such as sodium amide, lithium diisopropylamide
and the like; and Grignard reagents such as methyl magnesium
bromide and the like. The inert solvent includes, for example,
alcohols such as methanol, ethanol, isopropyl alcohol, ethylene
glycol and the like; ethers such as diethyl ether, tetrahydrofuran,
1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as
benzene, toluene, xylene and the like; esters such as ethyl
acetate, ethyl formate and the like; amides such as
N,N-dimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide
and the like; acetonitrile; dimethyl sulfoxide; pyridine;
chloroform; dichloromethane; water; and mixtures of solvents
selected from these inert solvents.
[0188] When L.sup.2 is not an iodide atom, L.sup.2 can be converted
to an iodine atom before performing the next step by using sodium
iodide or potassium iodide in an inert solvent.
Step 4:
[0189] L.sup.2 in Compound (6) can be converted to the cyano group
by reacting compound (6) with a cyanide in the presence or absence
of a phase transfer catalyst or a Crown ether in an inert solvent.
Herein, the cyanide includes, for example, potassium cyanide,
sodium cyanide and the like. The phase transfer catalyst includes,
for example, tetrabutylammonium chloride, tetrabutylammonium
bromide, tetrabutylammonium iodide, tetrabutylammonium
hydrogensulfate, tetraethylammonium chloride, tetraethylammonium
bromide, tetraethylammonium iodide, benzyltributylammonium
chloride, benzyltributylammonium bromide, benzyltributylammonium
iodide, benzyltriethylammonium chloride, benzyltriethylammonium
bromide, benzyltriethylammonium iodide and the like. The Crown
ether includes, for example, 15-Crown-5,18-Crown-6 and the like.
The inert solvent includes, for example, alcohols such as methanol,
ethanol, isopropyl alcohol, ethylene glycol and the like; ethers
such as diethyl ether, tetrahydrofuran, 1,4-dioxane,
1,2-dimethoxyethane and the like; hydrocarbons such as benzene,
toluene, xylene and the like; esters such as ethyl acetate, ethyl
formate and the like; amides such as N,N-dimethylformamide,
N-methylpyrrolidone, N,N-dimethylacetamide and the like;
acetonitrile; dimethyl sulfoxide; pyridine; chloroform;
dichloromethane; water; and mixtures of solvents selected from
these inert solvents.
Step 5:
[0190] The cyano group in Compound (7) can be converted to a
carboxy group or a carbamoyl group in the same method as described
in step 2.
##STR00053##
Step 6:
[0191] Compound (6) can be converted to Compound (9) by reacting
Compound (6) with the trialkyl phosphite. Herein, the trialkyl
phosphite includes, for example, trimethyl phosphite, triethyl
phosphite, triisopropyl phosphite and the like.
Step 7:
[0192] The phosphate ester group in Compound (9) can be hydrolyzed
by using an acid or a base in an inert solvent. Herein, the acid
includes, for example, organic acids such as formic acid, acetic
acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic
acid, p-toluenesulfonic acid, benzoic acid,
trifluoromethanesulfonic acid and the like; inorganic acids such as
sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric
acid, polyphosphoric acid, nitric acid or the like. The base
includes, for example, sodium carbonate, potassium carbonate,
sodium hydrogencarbonate, potassium hydrogencarbonate, sodium
hydroxide, potassium hydroxide, barium hydroxide, sodium hydride,
potassium hydride and the like; metal alcoholates such as sodium
methoxide, sodium ethoxide, potassium tert-butoxide and the like.
The inert solvent includes, for example, alcohols such as methanol,
ethanol, isopropyl alcohol, ethylene glycol and the like; ethers
such as diethyl ether, tetrahydrofuran, 1,4-dioxane,
1,2-dimethoxyethane and the like; hydrocarbons such as benzene,
toluene, xylene and the like; esters such as ethyl acetate, ethyl
formate and the like; amides such as N,N-dimethylformamide,
N-methylpyrrolidone, N,N-dimethylacetamide and the like;
acetonitrile; dimethyl sulfoxide; pyridine; water; and mixtures of
solvents selected from these inert solvents.
Step 8:
[0193] Compound (11) can be obtained by reacting Compound (6) with
a sulfite in the presence or absence of a phase transfer catalyst
or a Crown ether in an inert solvent. Herein, the sulfite includes,
for example, sodium sulfite, potassium sulfite and the like. The
phase transfer catalyst includes, for example, tetrabutylammonium
chloride, tetrabutylammonium bromide, tetrabutylammonium iodide,
tetrabutylammonium hydrogensulfate, tetraethylammonium chloride,
tetraethylammonium bromide, tetraethylammonium iodide,
benzyltributylammonium chloride, benzyltributylammonium bromide,
benzyltributylammonium iodide, benzyltriethylammonium chloride,
benzyltriethylammonium bromide, benzyltriethylammonium iodide and
the like. The Crown ether includes, for example,
15-Crown-5,18-Crown-6 and the like. The inert solvent includes, for
example, alcohols such as methanol, ethanol, isopropyl alcohol,
ethylene glycol and the like; ethers such as diethyl ether,
tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like;
hydrocarbons such as benzene, toluene, xylene and the like; esters
such as ethyl acetate, ethyl formate and the like; amides such as
N,N-dimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide
and the like; acetonitrile; dimethyl sulfoxide; pyridine; water;
and mixtures of solvents selected from these inert solvents.
##STR00054##
Step 9:
[0194] When X.sup.b is not hydroxy, Compound (13), a compound of
the present invention, can be synthesized from Compound (12) by
conventional methods for amidating a carboxyl group, esterification
of a carboxyl group or alkylation of a carboxy group in the
presence or absence of a base in an inert solvent. Conventional
methods for amidating a carboxyl group or esterification of a
carboxyl group are: for example, the reaction via a mixed acid
anhydride obtained by the reaction of Compound (12) with haloformic
acid ester (e.g., ethyl chloroformate or isobutyl chloroformate) or
an acid chloride (e.g., benzoyl chloride or pivaloyl chloride); the
reaction in the presence of a condensing agent such as
N,N'-dicyclohexylcarbodiimide (DCC),
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCl),
carbonyldiimidazole (CDI), diphenylphosphorylazide (DPPA), diethyl
cyanophosphate or the like, and optionally an additive such as
1-hydroxybenzotriazole (HOBt), N-hydroxysuccinimide,
4-dimethylaminopyridine or the like; or the reaction via an acid
halide obtained by the reaction of Compound (12) with a
halogenating reagent such as thionyl chloride, oxalyl chloride, or
the like; conventional methods for alkylation of a carboxy group is
the reaction with an alkylating reagent such as alkylhalide or
alkylsulfonate in the presence or absence of an additive to
accelerate the reaction such as NaI and KI. When R.sup.9 contains
an alkoxycarbonyl group, the alkoxycarbonyl group can be converted
to the carboxy group by using a method as described in Protective
Group in Organic Synthesis (T. W. Greene, P. G. M. Wuts; 3.sup.rd
ed., 1999, John Wiley & sons, Inc.). The base includes amines
such as triethylamine, N,N-diisopropylethylamine, pyridine,
1,8-diazabicyclo[5.4.0]undec-7-ene and the like; inorganic bases
such as sodium carbonate, potassium carbonate, sodium
hydrogencarbonate, potassium hydrogencarbonate, sodium hydroxide,
potassium hydroxide, lithium hydroxide, barium hydroxide, sodium
hydride and the like; metal alcoholates such as sodium methoxide,
sodium ethoxide, potassium tert-butoxide and the like. The acid
includes, for example, organic acids such as formic acid, acetic
acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic
acid, p-toluenesulfonic acid, benzoic acid,
trifluoromethanesulfonic acid and the like; inorganic acids such as
sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric
acid, polyphosphoric acid, nitric acid or the like. The inert
solvent includes, for example, alcohols such as methanol, ethanol,
isopropyl alcohol, ethylene glycol and the like; ethers such as
diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane
and the like; hydrocarbons such as benzene, toluene and the like;
amides such as N,N-dimethylformamide, N-methylpyrrolidone,
N,N-dimethylacetamide and the like; acetonitrile; dimethyl
sulfoxide; pyridine; chloroform; dichloromethane; water; and
mixtures of solvents selected from these inert solvents.
##STR00055##
Step 10:
[0195] Compound (15), a compound of the present invention, can be
obtained by reacting Compound (6) with Compound (14) in the
presence or absence of a base in an inert solvent. The base
includes amines such as triethylamine, N,N-diisopropylethylamine,
pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene and the like;
inorganic bases such as sodium carbonate, potassium carbonate,
sodium hydrogencarbonate, potassium hydrogencarbonate, sodium
hydride and the like; metal alcoholates such as sodium methoxide,
sodium ethoxide, potassium tert-butoxide and the like. The inert
solvent includes, for example, alcohols such as methanol, ethanol,
isopropyl alcohol, ethylene glycol and the like; ethers such as
diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane
and the like; hydrocarbons such as benzene, toluene and the like;
amides such as N,N-dimethylformamide, N-methylpyrrolidone,
N,N-dimethylacetamide and the like; acetonitrile; dimethyl
sulfoxide; pyridine; chloroform; dichloromethane; water; and
mixtures of solvents selected from these inert solvents.
##STR00056##
Step 11:
[0196] Compound (18) can be obtained by reacting Compound (16) with
Compound (17) in the presence or absence of a base in an inert
solvent or without any solvent. The base includes amines such as
triethylamine, N,N-diisopropylethylamine, or pyridine and the like;
inorganic bases such as sodium carbonate, potassium carbonate,
sodium hydrogencarbonate, potassium hydrogencarbonate, sodium
hydroxide, potassium hydroxide, barium hydroxide, sodium hydride
and the like; metal alcoholates such as sodium methoxide, sodium
ethoxide, potassium tert-butoxide and the like. The inert solvent
includes, for example, alcohols such as methanol, ethanol,
isopropyl alcohol, ethylene glycol and the like; ethers such as
diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane
and the like; hydrocarbons such as benzene, toluene and the like;
amides such as N,N-dimethylformamide, N-methylpyrrolidone,
N,N-dimethylacetamide and the like; acetonitrile; dimethyl
sulfoxide; pyridine; chloroform; dichloromethane; water; and
mixtures of solvents selected from these inert solvents.
[0197] The compound of the present invention can be converted to a
salt in an inert solvent with an inorganic acid such as sulfuric
acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric
acid or the like, with an organic acid such as acetic acid, oxalic
acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric
acid, benzenesulfonic acid, methanesulfonic acid, p-toluenesulfonic
acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid,
glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid,
malic acid, malonic acid, mandelic acid, galactaric acid,
naphthalene-2-sulfonic acid or the like, with an inorganic base
such as lithium hydroxide, sodium hydroxide, potassium hydroxide,
calcium hydroxide, magnesium hydroxide, zinc hydroxide, aluminum
hydroxide or the like or with an organic base such as ammonia,
arginine, lysine, piperazine, choline, diethylamine,
4-phenylcyclohexylamine, 2-aminoethanol, benzathine or the like.
The inert solvent includes, for example, alcohols such as methanol,
ethanol, isopropyl alcohol, ethylene glycol and the like; ethers
such as diethyl ether, diisopropyl ether, tetrahydrofuran,
1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as
benzene, toluene and the like; esters such as ethyl acetate, ethyl
formate and the like; ketones such as acetone, methylethylketone
and the like; amides such as N,N-dimethylformamide,
N-methylpyrrolidone, N,N-dimethylacetamide and the like;
acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide;
pyridine; water; and mixtures of solvents selected from these inert
solvents.
[0198] The compound of the present invention is useful as a
therapeutic or prophylactic agent for diseases in which CRF is
considered to be involved. For this purpose, the compound of the
present invention can be formulated into tablets, pills, capsules,
granules, powders, solutions, emulsions, suspensions, injections
and the like by a conventional preparation technique by adding
conventional fillers, binders, disintegrators, pH-adjusting agents,
solvents, etc.
[0199] The compound of the present invention can be administered to
an adult patient in a dose of 0.1 to 500 mg per day in one portion
or several portions orally or parenterally. The dose can be
properly increased or decreased depending on the kind of a disease
and the age, body weight and symptom of a patient.
EMBODIMENTS OF THE INVENTION
[0200] The present invention is concretely explained with reference
to the following examples and test example, but is not limited
thereto.
Example 1
Synthesis of
{1-[1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-acetic acid (compound 1-013)
##STR00057##
[0202] (1) Under N.sub.2 atmosphere, to a mixture of
1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-
-ol (1.5 g), triethylamine (1.0 g) in CHCl.sub.3 (9 mL),
trifluoromethanesulfonic anhydride (1.0 mL) was added with cooling
in an ice bath and the mixture was stirred for 30 minutes. The
reaction was quenched with water and the mixture was extracted with
CHCl.sub.3. The organic phase was washed with saturated aqueous
NaHCO.sub.3 solution, dried over anhydrous MgSO.sub.4 and filtered.
The filtrate was concentrated under reduced pressure to obtain
crude trifluoromethanesulfonic acid
1-(4-methoxy-2,6-dimethylphenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4--
yl ester (2.19 g). This material was used in the next step without
further purification.
##STR00058##
[0203] (2) A mixture of crude trifluoromethanesulfonic acid
1-(4-methoxy-2,6-dimethylphenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4--
yl ester (1.1 g), N,N-diisopropylethylamine (0.65 g) and
piperidin-4-yl-acetonitrile (1.6 g) was heated at 150.degree. C. in
a sealed tube for 7 hours. After cooling to room temperature, ethyl
acetate and water were poured into the mixture, and separated. The
aqueous phase was extracted with ethyl acetate, and the organic
phase was dried over MgSO.sub.4 and filtered. The filtrate was
concentrated under reduced pressure and the residue was purified
with column chromatography (silica gel: Wako gel C200, eluent:
hexane:ethyl acetate=3/1) to obtain
{1-[1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-acetonitrile (0.58 g) as a pale yellow
crystal.
##STR00059##
[0204] (3) A mixture of
{1-[1-(4-methoxy-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-acetonitrile (0.40 g) and conc. HCl (4 mL)
was heated at reflux for 5 hours. After cooling to room
temperature, conc. HCl was removed under reduced pressure. A
saturated aqueous NaHCO.sub.3 solution and CHCl.sub.3 were added to
the residue and separated. The aqueous phase was extracted with
CHCl.sub.3. The organic phase was washed with 5% aqueous KHSO.sub.4
solution, dried over MgSO.sub.4 and filtered. The filtrate was
concentrated under reduced pressure and the residue was purified
with column chromatography (silica gel: Wako gel C200, eluent:
CHCl.sub.3: methanol=40/1) and the resulting solid was washed with
methanol to obtain the title compound (0.21 g).
Example 2
Synthesis of
3-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-piperidin-4-yl}-propionamide (compound 1-040)
##STR00060##
[0206] (1) A suspension of
7-(4-bromo-2,6-dimethyl-phenyl)-4-chloro-2,5,6-trimethyl-7H-pyrrolo[2,3-d-
]pyrimidine (2.0 g), 3-(piperidin-4-yl)propionitrile (1.4 g) and
N,N-diisopropylethylamine (1.4 g) in EtOH (4 mL) was heated at
100.degree. C. in a sealed tube for 11 hours. After cooling to room
temperature, the solvent was removed under reduced pressure. The
residue was purified with column chromatography (silica gel: Wako
gel C200, eluent: hexane:ethyl acetate: CHCl.sub.3=8/2/1) to obtain
3-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-piperidin-4-yl}-propionitrile (2.0 g) as a white
crystal.
##STR00061##
[0207] (2) To
3-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-piperidin-4-yl}-propionitrile (0.40 g),
H.sub.2SO.sub.4 (4 mL) was added and the mixture was stirred at
room temperature for 5 hours. The reaction mixture was poured into
ice, and then was made to alkaline by adding 4 M aqueous NaOH
solution. The mixture was extracted with ethyl acetate and the
organic phase and the organic phase was dried over
Na.sub.2SO.sub.4. The desiccant was removed by filtration and the
filtrate was concentrated under reduced pressure. The residue was
purified with column chromatography (silica gel: Wako gel C200,
eluent: CHCl.sub.3: methanol=60/1) to obtain an oil. The oily
product was crystallized from diethylether to obtain the title
compound (0.33 g) as a white crystal.
Example 3
Synthesis of
(2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyri-
din-4-yl]-piperidin-4-yl}-ethyl)-phosphonic acid hydrochloride
(compound 1-046)
##STR00062##
[0209] (1) To a solution of
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-ethanol (0.93 g), which was prepared in
the similar method as shown in example 1, in CHCl.sub.3 (10 mL),
was added methanesulfonyl chloride (0.47 g) and pyridine (0.64 g)
and the mixture was stirred at room temperature for 3 hours. Water
was added into the reaction mixture and the mixture was extracted
with CHCl.sub.3. The organic phase was washed with water and brine,
dried over Na.sub.2SO.sub.4 and filtered. The filtrate was
concentrated under reduced pressure to obtain a brown oil. The oily
product was crystallized from diisopropylether to obtain
methanesulfonic acid
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-ethyl ester (1.0 g).
##STR00063##
[0210] (2) A mixture of methanesulfonic acid
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-ethyl ester (0.70 g) and NaI (0.59 g) in
acetone (14 mL) was heated at reflux for 3 hours. After cooling to
room temperature, water was added and the mixture was extracted
with ethyl acetate. The organic phase was washed with water, dried
over Na.sub.2SO.sub.4 and filtered. The filtrate was concentrated
under reduced pressure. The residue was purified with column
chromatography (silica gel: Wako gel C200, eluent: hexane:ethyl
acetate=10/1) to obtain
1-(4-bromo-2,6-dimethyl-phenyl)-4-[4-(2-iodo-ethyl)-piperidin-1-yl]-3,6-d-
imethyl-1H-pyrrolo[2,3-b]pyridine (0.65 g) as a white crystal.
##STR00064##
[0211] (3) Under N.sub.2 atmosphere, a mixture of
1-(4-bromo-2,6-dimethyl-phenyl)-4-[4-(2-iodo-ethyl)-piperidin-1-yl]-3,6-d-
imethyl-1H-pyrrolo[2,3-b]pyridine (0.25 g) and triethyl phosphite
(10 mL) was heated at 160.degree. C. for 4.5 hours. After the
reaction was completed, excess triethyl phosphate was removed under
reduced pressure. The residue was purified with column
chromatography (silica gel: Wako gel C200, eluent: hexane:ethyl
acetate=1/1) to obtain a colorless oil. The oily product was
crystallized from diisopropylether (10 mL) to provide
(2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyri-
din-4-yl]-piperidin-4-yl}-ethyl)-phosphonic acid diethyl ester
(0.16 g) as a white crystal.
##STR00065##
[0212] (4) A mixture of
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-ethyl)-phosphonic acid diethyl ester (67
mg) and 6 M HCl (4 mL) was heated at reflux for 10 hours. And then
12 M HCl (2 mL) was added and the reaction mixture was heated at
reflux for 10 hours. The reaction mixture was concentrated under
reduced pressure to obtain the title compound as an amorphous (13
mg).
Example 4
Synthesis of
2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyrid-
in-4-yl]-piperidin-4-yl}-ethanesulfonic acid (compound 1-048)
##STR00066##
[0214] A mixture of
1-(4-bromo-2,6-dimethyl-phenyl)-4-[4-(2-iodo-ethyl)-piperidin-1-yl]-3,6-d-
imethyl-1H-pyrrolo[2,3-b]pyridine (0.25 g), Na.sub.2SO.sub.3 (0.28
g), tetrabutylammonium iodide (16 mg), ethanol (5 mL),
tetrahydrofuran (5 mL) and water (3 mL) was heated at reflux for 10
hours. The reaction mixture was concentrated under reduced
pressure. The residue was purified with column chromatography
(silica gel: Wako gel C200, eluent: ethyl acetate: methanol=5/1) to
obtain the title compound (56 mg) as a yellow amorphous.
Example 5
Synthesis of
{1-[1-(4-bromo-2,6-dimethylphenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin--
4-yl]piperidin-4-yl}acetic acid ethyl ester hydrochloride (compound
1-050)
##STR00067##
[0216] To a solution of
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid (100 mg) in CHCl.sub.3 (4 mL) in
an ice cooling bath was added ethanol (20 mg),
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (61
mg), and dimethylaminopyridine (26 mg), and the mixture was stirred
at room temperature for 1 hour. The reaction mixture was poured
into ethyl acetate and water, and separated. The organic phase was
washed with brine, dried over Na.sub.2SO.sub.4, and filtered. The
filtrate was concentrated under reduced pressure and the residue
was purified with column chromatography (silica gel: Wako gel C200,
eluent: hexane:ethyl acetate=4/1) to obtain
{1-[1-(4-bromo-2,6-dimethylphenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin--
4-yl]piperidin-4-yl}acetic acid ethyl ester (99 mg).
{1-[1-(4-Bromo-2,6-dimethylphenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin--
4-yl]piperidin-4-yl}acetic acid ethyl ester was dissolved in
ethanol (2 mL) and 4 M HCl in ethyl acetate solution (60 .mu.L) was
added into the solution with cooling in an ice bath. After stirring
at room temperature, the reaction mixture was concentrated under
reduced pressure, and the residue was crystallized from
diisopropylether (1 mL). The crystal was collected by filtration to
obtain the title compound. (95 mg)
Example 6
Synthesis of
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid 1-cyclohexyloxycarbonyloxy-ethyl
ester (compound 1-071)
##STR00068##
[0218] A suspension of
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid hydrochloride (300 mg),
1-chloroethyl cyclohexyl carbonate (293 mg), potassium carbonate
(196 mg) and NaI (213 mg) in DMF (3 mL) was heated at 60.degree. C.
for 3 hours. After cooling to room temperature, water was added and
the mixture was extracted with ethyl acetate. The organic phase was
washed with brine and concentrated under reduced pressure. The
residue was purified with column chromatography (silica gel: Wako
gel C200, eluent: hexane:ethyl acetate=4/1) to obtain the title
compound (225 mg) as a colorless oil.
Example 7
Synthesis of
(S)-2-(2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3--
b]pyridin-4-yl]-piperidin-4-yl}-acetylamino)-3-phenyl-propionic
acid (compound 1-074)
##STR00069##
[0220] (1) To a solution of
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid hydrochloride (300 mg),
L-phenylalanine ethyl ester hydrochloride (204 mg),
1-hydroxybenzotriazole (108 mg) and triethylamine (90 mg) in DMF (3
mL) in an ice cooling bath was added
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (170
mg), and the mixture was stirred at room temperature for 4 hours.
Water was added into the reaction mixture and the mixture was
extracted with ethyl acetate. The organic phase was washed with a
saturated aqueous NaHCO.sub.3 solution and brine, and concentrated
under reduced pressure. The residue was purified with column
chromatography (silica gel: Wako gel C200, eluent: hexane:ethyl
acetate=1/1) to obtain
(S)-2-(2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3--
b]pyridin-4-yl]-piperidin-4-yl}-acetylamino)-3-phenyl-propionic
acid ethyl ester (222 mg) as a colorless oil.
##STR00070##
[0221] (2) A mixture of
(S)-2-(2-{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3--
b]pyridin-4-yl]-piperidin-4-yl}-acetylamino)-3-phenyl-propionic
acid ethyl ester (140 mg), 4 M NaOH (1 mL) and EtOH (2 mL) was
stirred at room temperature for 24 hours. 1 M KHSO.sub.4 (10 mL)
was added into the reaction mixture and the mixture was extracted
with ethyl acetate. The organic phase was washed with brine, and
concentrated under reduced pressure. The residue was purified with
column chromatography (silica gel: Wako gel C200, eluent:
CHCl.sub.3: MeOH=9/1) to obtain the title compound (35 mg) as an
amorphous.
Example 8
Synthesis of
4-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-piperidin-4-yl}-2-cyano-butyric acid ethyl ester
(compound 1-063)
##STR00071##
[0223] Under N.sub.2 atmosphere, to a solution of cyanoacetic acid
ethyl ester (93 mg) in THF (3 mL) was added sodium hydride (33 mg)
and the mixture was stirred for 30 minutes. Methanesulfonic acid
2-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-piperidin-4-yl}-ethyl ester (300 mg) was added, and
the mixture was heated at reflux for 3 hours. Cyanoacetic acid
ethyl ester (93 mg) was added, and the reaction mixture was heated
at reflux for 1 hour. And then NaI (7 mg) was added, and the
mixture was heated at reflux for 2 hours. After cooling to room
temperature, 5% aqueous KHSO.sub.4 solution was added into the
reaction mixture and the mixture was extracted with ethyl acetate.
The organic phase was dried over MgSO.sub.4 and filtered and the
filtrate was concentrated under reduced pressure. The residue was
purified with column chromatography (silica gel: Wako gel C200,
eluent: hexane:ethyl acetate=4/1) to obtain the title compound (57
mg) as a colorless oil.
Example 9
Synthesis of
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetic acid
##STR00072##
[0225] (1) A mixture of
1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-y-
lamine (10.0 g), methanesulfonic acid
3-cyanomethyl-5-methanesulfonyloxy-pentyl ester (11.3 g) and
N,N-diisopropylethylamine (8.25 g) in N-methylpyrrolidone (10 mL)
was heated at 135.degree. C. for 4 hours. Methanesulfonic acid
3-cyanomethyl-5-methanesulfonyloxy-pentyl ester (2.60 g) was added
to the reaction mixture and the mixture was heated at 135.degree.
C. for 4.5 hours. After cooling to room temperature, the reaction
mixture was poured into a mixture of ethyl acetate, hexane and
water (10/1/3), and separated. The aqueous phase was extracted with
a mixture of ethyl acetate and hexane (10/1). The combined organic
phase was washed with brine, dried over MgSO.sub.4, and filtered,
and concentrated under reduced pressure. The residue was purified
with column chromatography (silica gel: Wako gel C200, eluent:
hexane:ethyl acetate: CHCl.sub.3=4/1/0.5) to obtain a solid. The
solid was crystallized from diisopropylether to obtain
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetonitrile (8.61 g) as a solid.
##STR00073##
[0226] (2) A mixture of
{1-[1-(4-bromo-2,6-dimethyl-phenyl)-3,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-
-4-yl]-piperidin-4-yl}-acetonitrile (10.0 g) and conc. HCl (100 mL)
was heated at reflux for 10 h. After evaporating conc. HCl under
reduced pressure. To the residue, aqueous NaHCO.sub.3 solution and
CHCl.sub.3 were added and partitioned. The organic phase was washed
with H.sub.2O, 1M aqueous KHSO.sub.4 solution and brine, dried over
Na.sub.2SO.sub.4, and filtered, and concentrated under reduced
pressure. The residue was purified with column chromatography
(silica gel: Wako gel C200, eluent: hexane:ethyl acetate=1/1) to
obtain a solid. The solid was recrystallized from EtOH and washed
with H.sub.2O to give the title compound (6.0 g) as a crystal.
Reference Example 1
Synthesis of methanesulfonic acid
3-cyanomethyl-5-methanesulfonyloxy-pentyl ester
##STR00074##
[0228] (1) To a solution of 3-oxo-pentanedioic acid dimethyl ester
(523 g) in toluene (750 mL), cyanoacetic acid (511 g), NH.sub.4OAc
(46.3 g) and acetic acid (90.1 g) were added and heated at reflux
with dehydrating by Dean-Stark apparatus for 8 h. After cooling to
room temperature, the reaction mixture was washed with water,
saturated aqueous NaHCO.sub.3 solution and brine. The organic phase
was dried over MgSO.sub.4, filtered, and concentrated under reduced
pressure to give crude 3-cyanomethylene-pentanedioic acid dimethyl
ester (403 g) as an oil. .sup.1H NMR (200 MHz, CDCl.sub.3) .delta.
ppm 3.39 (d, J=0.88Hz, 2H), 3.62 (s, 2H), 3.72 (s, 3H), 3.74 (s,
3H), 5.51 (s, 1H).
##STR00075##
[0229] (2) To a solution of crude 3-cyanomethylene-pentanedioic
acid dimethyl ester (403 g) in methanol (500 mL), 5% Pd--C was
added and the mixture was stirred at room temperature for 4 days.
The Pd--C was removed by filtration and the filtrate was
concentrated under reduced pressure to give crude
3-cyanomethyl-pentanedioic acid dimethyl ester (212 g). The residue
was purified by distillation to obtain 3-cyanomethyl-pentanedioic
acid dimethyl ester (bp 130-150.degree. C., 133 Pa) as a yellow
oil. .sup.1H NMR (200 MHz, CDCl.sub.3) .delta. ppm 2.46-2.61 (m,
5H) 2.62-2.78 (m, 4H) 3.71 (s, 6H).
##STR00076##
[0230] (3) Under nitrogen atmosphere, 3-cyanomethyl-pentanedioic
acid dimethyl ester (212 g) was added to a suspension of
LiAlH.sub.4 (50.0 g) in THF (1.8 L) at -20.degree. C. After
stirring for 30 min., H.sub.2O (200 mL) was slowly added to the
reaction mixture. The insoluble material was removed by filtration
and the filtrate was concentrated under reduced pressure to obtain
5-hydroxy-3-(2-hydroxy-ethyl)-pentanenitrile (131 g). .sup.1H NMR
(200 MHz, CDCl.sub.3) .delta. ppm 1.38-1.91 (m, 4H) 1.98-2.36 (m,
1H) 2.50 (d, J=5.71Hz, 2H) 3.51-3.90 (m, 4H).
##STR00077##
[0231] (4) Under nitrogen atmosphere, a solution of
5-hydroxy-3-(2-hydroxy-ethyl)-pentanenitrile (100 g) and Et.sub.3N
(170 g) in THF (500 mL) was cooled to -15.degree. C. and MsCl (168
g) was added slowly and the reaction mixture was stirred at room
temperature for 1.5 h. After adding H.sub.2O (1.2 L) into the
reaction mixture, and the mixture was stirred at room temperature
for 30 min. The precipitate was collected by filtration and dried
to obtain the title compound (145 g) as a pale brown crystal.
.sup.1H NMR (200 MHz, CDCl.sub.3) .delta. ppm 1.65-2.09 (m, 5H)
2.68 (d, J=5.75Hz, 2H) 3.20 (s, 6H) 4.29 (t, J=6.45Hz, 4H).
TABLE-US-00001 TABLE 1.sup.*1 ##STR00078## Com. No. Ex. No
##STR00079## Y R.sup.6 R.sup.7 R.sup.8 --Ar melting point (.degree.
C.) (solvent for crystallization) 1-001 1 ##STR00080## N CH.sub.3
CH.sub.3 CH.sub.3 ##STR00081## 205-207 (EtOAc) 1-002 1 ##STR00082##
N CH.sub.3 CH.sub.3 H ##STR00083## 229-231 (EtOAc) 1-003 1
##STR00084## CH CH.sub.3 CH.sub.3 CH.sub.3 ##STR00085##
140-142.sup.*2 (Et.sub.2O) 1-004 1 ##STR00086## CH CH.sub.3
CH.sub.3 H ##STR00087## 223-225 (EtOH/EtOAc) 1-005 1 ##STR00088##
CH CH.sub.3 CH.sub.3 CH.sub.3 ##STR00089## 144-146 (EtOAc) 1-006 1
##STR00090## CH CH.sub.3 CH.sub.3 H ##STR00091## 207-209 (EtOAc)
1-007 1 ##STR00092## CH CH.sub.3 CH.sub.3 CH.sub.3 ##STR00093##
148-150 (EtOAC) 1-008 1 ##STR00094## CH CH.sub.3 CH.sub.3 H
##STR00095## 208-210 (EtOAc) 1-009 1 ##STR00096## CH CH.sub.3
CH.sub.3 H ##STR00097## 236-238 (EtOAc) 1-010 1 ##STR00098## CH
CH.sub.3 CH.sub.3 H ##STR00099## 230-232 (EtOAc) 1-011 1
##STR00100## CH CH.sub.3 CH.sub.3 H ##STR00101## 231-233 (EtOAc)
1-012 1 ##STR00102## CH CH.sub.3 CH.sub.3 H ##STR00103## 235-237
(EtOAc) 1-013 1 ##STR00104## CH CH.sub.3 CH.sub.3 H ##STR00105##
215-217 (MeOH) 1-014 1 ##STR00106## CH CH.sub.3 CH.sub.3 H
##STR00107## 193-195 (EtOAc) 1-015 1 ##STR00108## CH CH.sub.3
CH.sub.3 H ##STR00109## 216-218 (EtOAc) 1-016 1 ##STR00110## CH
CH.sub.3 CH.sub.3 H ##STR00111## 233-235 (EtOAc) 1-017 1
##STR00112## N CH.sub.3 CH.sub.3 CH.sub.3 ##STR00113## 255-257
(EtOH/EtOAc) 1-018 1 ##STR00114## N CH.sub.3 CH.sub.3 H
##STR00115## 277-279 (EtOAc) 1-019 1 ##STR00116## CH CH.sub.3
CH.sub.3 CH.sub.3 ##STR00117## 271-273 (EtOAc) 1-020 1 ##STR00118##
CH CH.sub.3 CH.sub.3 H ##STR00119## 275-277 (decomp.) (EtOAc/EtOH)
1-021 1 ##STR00120## CH CH.sub.3 CH.sub.3 CH.sub.3 ##STR00121##
249-251 (EtOAc) 1-022 1 ##STR00122## CH CH.sub.3 CH.sub.3 H
##STR00123## 261-263 (EtOAc) 1-023 1 ##STR00124## CH CH.sub.3
CH.sub.3 CH.sub.3 ##STR00125## 275-277 (EtOAc) 1-024 1 ##STR00126##
CH CH.sub.3 CH.sub.3 H ##STR00127## 232-234 (EtOAc) 1-025 1
##STR00128## CH CH.sub.3 CH.sub.3 H ##STR00129## 265-267 (EtOAc)
1-026 1 ##STR00130## CH CH.sub.3 CH.sub.3 H ##STR00131## 254-256
(EtOAc) 1-027 1 ##STR00132## CH CH.sub.3 CH.sub.3 H ##STR00133##
260-262 (EtOAc) 1-028 1 ##STR00134## CH CH.sub.3 CH.sub.3 H
##STR00135## 253-255 (EtOAc/IPE) 1-029 1 ##STR00136## CH CH.sub.3
CH.sub.3 H ##STR00137## 232-234 (EtOAc) 1-030 1 ##STR00138## CH
CH.sub.3 CH.sub.3 H ##STR00139## 250-252 (EtOAc) 1-031 1
##STR00140## CH CH.sub.3 CH.sub.3 H ##STR00141## 248-250 (EtOAc)
1-032 1 ##STR00142## CH CH.sub.3 CH.sub.3 CH.sub.3 ##STR00143##
181-183 (EtOAc) 1-033 1 ##STR00144## CH CH.sub.3 CH.sub.3 H
##STR00145## 200-202 (EtOAc) 1-034 1 ##STR00146## CH CH.sub.3
CH.sub.3 H ##STR00147## 244-246 (EtOAc) 1-035 1 ##STR00148## CH
CH.sub.3 CH.sub.3 H ##STR00149## 250-252 (EtOAc) 1-036 1
##STR00150## CH CH.sub.3 CH.sub.3 H ##STR00151## 251-253 (EtOAc)
1-037 2 ##STR00152## N CH.sub.3 CH.sub.3 CH.sub.3 ##STR00153##
254-256 (IPE/EtOAc) 1-038 2 ##STR00154## N CH.sub.3 CH.sub.3 H
##STR00155## 252-254 (IPE/EtOAc) 1-039 2 ##STR00156## CH CH.sub.3
CH.sub.3 H ##STR00157## 214-216.sup.*2 (EtOAc/EtOH) 1-040 2
##STR00158## N CH.sub.3 CH.sub.3 CH.sub.3 ##STR00159## 126-128
(Et.sub.2O) 1-041 2 ##STR00160## N CH.sub.3 CH.sub.3 H ##STR00161##
233-235 (IPE/EtOAc) 1-042 2 ##STR00162## CH CH.sub.3 CH.sub.3 H
##STR00163## 215-216.sup.*2 (EtOAc/EtOH) 1-043 3 ##STR00164## CH
CH.sub.3 CH.sub.3 H ##STR00165## 137-139 (IPE) 1-044 3 ##STR00166##
CH CH.sub.3 CH.sub.3 H ##STR00167## 127-128 (IPE) 1-045 3
##STR00168## CH CH.sub.3 CH.sub.3 H ##STR00169## amorphous.sup.*2
1-046 3 ##STR00170## CH CH.sub.3 CH.sub.3 H ##STR00171##
amorphous.sup.*2 1-047 4 ##STR00172## CH CH.sub.3 CH.sub.3 H
##STR00173## amorphous 1-048 4 ##STR00174## CH CH.sub.3 CH.sub.3 H
##STR00175## amorphous 1-049 1 ##STR00176## CH CH.sub.3 CH.sub.3 H
##STR00177## 208-210.sup.*2 (EtOH/EtOAc) 1-050 5 ##STR00178## CH
CH.sub.3 CH.sub.3 H ##STR00179## 146-148.sup.*2 (IPE) 1-051 1
##STR00180## N CH.sub.3 CH.sub.3 H ##STR00181## 178-180.sup.*3
1-052 1 ##STR00182## N CH.sub.3 CH.sub.3 H ##STR00183## 191-193
(IPE) 1-053 1 ##STR00184## N CH.sub.3 CH.sub.3 H ##STR00185##
136-138.sup.*2 (EtOAc) 1-054 1 ##STR00186## N CH.sub.3 CH.sub.3 H
##STR00187## 141-143.sup.*2 (EtOAc) 1-055 1 ##STR00188## N CH.sub.3
CH.sub.3 H ##STR00189## 138-140.sup.*2 (EtOAc) 1-056 1 ##STR00190##
N CH.sub.3 CH.sub.3 CH.sub.3 ##STR00191## 212-214 (EtOAc) 1-057 1
##STR00192## N CH.sub.3 CH.sub.3 H ##STR00193## 202-204 (EtOAc)
1-058 1 ##STR00194## N CH.sub.3 CH.sub.3 H ##STR00195## 195-197
(IPE/EtOAc) 1-059 1 ##STR00196## N CH.sub.3 CH.sub.3 H ##STR00197##
229-231 (THF/EtOAc) 1-060 1 ##STR00198## N CH.sub.3 CH.sub.3 H
##STR00199## 164-166.sup.*2 (EtOAc) 1-061 2 ##STR00200## N CH.sub.3
CH.sub.3 CH.sub.3 ##STR00201## 248-250 (IPE) 1-062 2 ##STR00202## N
CH.sub.3 CH.sub.3 H ##STR00203## 263-265 (IPE) 1-063 8 ##STR00204##
N CH.sub.3 CH.sub.3 CH.sub.3 ##STR00205## amorphous 1-064 1
##STR00206## N CH.sub.3 CH.sub.3 H ##STR00207## 178-180.sup.*2
(EtOAc) 1-065 7 ##STR00208## CH CH.sub.3 CH.sub.3 H ##STR00209##
183-185 (EtOAc) 1-066 7 ##STR00210## CH CH.sub.3 CH.sub.3 H
##STR00211## 184-186 (EtOAc) 1-067 5 ##STR00212## CH CH.sub.3
CH.sub.3 H ##STR00213## amorphous 1-068 5 ##STR00214## CH CH.sub.3
CH.sub.3 H ##STR00215## amorphous 1-069 5 ##STR00216## CH CH.sub.3
CH.sub.3 H ##STR00217## amorphous 1-070 5 ##STR00218## CH CH.sub.3
CH.sub.3 H ##STR00219## oil 1-071 6 ##STR00220## CH CH.sub.3
CH.sub.3 H ##STR00221## oil 1-072 6 ##STR00222## CH CH.sub.3
CH.sub.3 H ##STR00223## oil 1-073 7 ##STR00224## CH CH.sub.3
CH.sub.3 H ##STR00225## oil 1-074 7 ##STR00226## CH CH.sub.3
CH.sub.3 H ##STR00227## 144-146.sup.*3 1-075 6 ##STR00228## CH
CH.sub.3 CH.sub.3 H ##STR00229## oil 1-076 7 ##STR00230## CH
CH.sub.3 CH.sub.3 H ##STR00231## oil 1-077 6 ##STR00232## CH
CH.sub.3 CH.sub.3 H ##STR00233## amorphous 1-078 2 ##STR00234## N
CH.sub.3 CH.sub.3 H ##STR00235## amorphous 1-079 1 ##STR00236## N
CH.sub.3 --CH.dbd.CH-- CH.dbd.CH-- ##STR00237## 256-258 (EtOAc)
1-080 1 ##STR00238## N CH.sub.3 --CH.sub.2--CH.sub.2--
CH.sub.2--CH.sub.2-- ##STR00239## 238-239 (EtOAc) 1-081 1
##STR00240## N CH.sub.3 CH.sub.3 H ##STR00241## 254-256.sup.*3
1-082 1 ##STR00242## N CH.sub.3 CH.sub.3 CH.sub.3 ##STR00243##
amorphous .sup.*1Com. No. = compound number, Ex. No. = example
number, solvent for crystallization: EtOAc = ethyl acetate, MeOH =
methanol, EtOH = ethanol, IPE = diisopropylether, Et.sub.2O =
diethylether THF = tetrahydrofuran
[0232] Analytical data of non-crystal compounds are described
below.
1-045:
[0233] MS (ES, Neg): 504 (M-1).sup.-, 506 (M+1).sup.-; NMR (300
MHz, DMSO-d6) .delta. 1.33-1.69 (4H, m), 1.75-2.13 (3H, m), 1.88
(6H, s), 2.42 (3H, d, J=1.1Hz), 2.47 (3H, s), 2.80-3.25 (2 H, m),
3.63-3.97 (2H, m), 6.77 (1H, br s), 7.19 (1H, br s), 7.50-7.62 (2H,
m).
1-046:
[0234] MS (ES, Neg): 518 (M-1).sup.-, 520 (M+1).sup.-; NMR (300
MHz, DMSO-d6) .delta. 1.18-1.98 (9H, m), 1.88 (6H, s), 2.42 (3H, d,
J=0.9Hz), 2.80-3.27 (2H, m), 3.65-3.94 (2H, m), 6.60-6.85 (1H, m),
7.08-7.22 (1H, m), 7.19 (1H, br s), 7.50-7.62 (2H, m).
1-047:
[0235] MS (ES, Neg): 504 (M-1).sup.-, 506 (M+1).sup.-; NMR (300
MHz, DMSO-d6) .delta. 1.30-2.53 (2H, m), 1.74-2.15 (3H, m), 1.84
(6H, s), 2.32 (3H, s), 2.43 (3H, d, J=1.1Hz), 2.47 (2H, d,
J=6.4Hz), 2.62-2.78 (2H, m), 3.36-3.52 (2H, m), 6.47 (1H, s),
6.94-6.98 (1H, m), 7.44 (2H, s).
1-048:
[0236] MS (ES, Neg): 518 (M-1).sup.-, 520 (M+1).sup.-; NMR (300
MHz, DMSO-d6) .delta. 1.20-1.87 (7H, m), 1.84 (6H, s), 2.40-2.60
(2H, m), 2.43 (3H, d, J=0.9Hz), 2.49 (3H, s), 2.60-2.75 (2 H, m),
3.41-3.55 (2H, m), 6.46 (1H, s), 6.94-6.97 (1H, m), 7.44 (2H,
s).
1-063:
[0237] MS (ES, Pos): 566 (M+1).sup.+, 568 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta.1.28-1.70 (6H, m), 1.35 (3H, t, J=7.1Hz),
1.72-2.12 (3H, m), 1.84 (6H, s), 1.94 (3H, s), 2.37 (3H, s), 2.49
(3H, s), 2.82-3.00 (2H, m), 3.46-3.55 (1H, m), 3.90-4.09 (2H, m),
4.30 (2H, q, J=7.1 Hz), 7.33 (2H, s).
1-067
[0238] MS (ES, Pos): 566 (M+1).sup.+, 568 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta. 0.90-1.35 (4H, m), 1.45-1.80 (10H, m),
1.82-2.05 (2H, m), 1.92 (6H, s), 2.36 (2H, d, J=7.00Hz), 2.44 (3 H,
s), 2.49 (3H, s), 2.70-2.85 (2H, m), 3.52-3.61 (2H, m), 3.92 (2H,
d, J=6.37Hz), 6.43 (1H, s), 6.59-6.64 (1H, m), 7.29 (2H, s).
1-068
[0239] MS (ES, Pos): 594 (M+1).sup.+, 596 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta. 1.50-1.65 (4H, m), 1.80-2.00 (1H, m), 1.92
(6H, s), 2.41 (2H, d, J=7.00Hz), 2.44 (3H, s), 2.45-2.49 (3H, m),
2.70-2.83 (2H, m), 3.50-3.62 (2H, m), 5.11 (2H, s), 6.42 (1H, s),
6.59-6.64 (1H, m), 7.25-7.40 (6H, m).
1-069
[0240] MS (ES, Pos): 555 (M+1).sup.+, 557 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta. 1.48-1.70 (4H, m), 1.78-1.95 (3H, m), 1.92
(6H, s), 2.25 (6H, s), 2.36 (2H, d, J=7.00Hz), 2.44 (3H, s),
2.46-2.50 (3H, m), 2.70-2.82 (2H, m), 3.52-3.62 (2H, m), 6.42 (1H,
s), 6.59-6.63 (1H, m), 7.29 (2H, s).
1-070
[0241] MS (ES, Pos): 606 (M+1).sup.+, 608 (M+3).sup.+; NMR (200
MHz, CDCl.sub.3) .delta. 1.42-1.78 (4H, m), 1.60 (3H, s), 1.69 (3H,
s), 1.73 (3H, s), 1.80-1.96 (1H, m), 1.92 (6H, s), 2.01-2.18 (4H,
m), 2.36 (2H, d, J=6.80Hz), 2.44 (3H, s), 2.46-2.51 (3H, m),
2.68-2.85 (2H, m), 3.49-3.63 (2H, m), 4.63 (2H, d, J=7.00Hz),
5.03-5.15 (2H, m), 5.30-5.42 (2H, m), 6.42 (1H, s), 6.58-6.63 (1H,
m), 7.29 (2H, s).
1-071
[0242] MS (ES, Pos): 640 (M+1).sup.+, 642 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta. 1.20-1.62 (10H, m), 1.54 (3H, d,
J=5.40Hz), 1.70-1.82 (2H, m), 1.82-2.04 (3H, m), 1.92 (6H, s),
2.37-2.42 (2H, m), 2.44 (3H, s), 2.46-2.50 (3H, m), 2.70-2.82 (2H,
m), 3.49-3.61 (2H, m), 4.58-4.70 (1H, m), 6.42 (1H, s), 6.59-6.63
(1H, m), 6.80 (1H, q, J=5.40Hz), 7.29 (2H, s).
1-072
[0243] MS (ES, Pos): 584 (M+1).sup.+, 586 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta. 1.23 (9H, s), 1.50-1.65 (4H, m), 1.82-1.91
(1H, m), 1.92 (6H, s), 2.43 (2H, d, J=6.99Hz), 2.45 (3H, s),
2.46-2.50 (3H, m), 2.71-2.82 (2H, m), 3.50-3.61 (2H, m), 5.79 (2H,
s), 6.42 (1H, s), 6.59-6.63 (1H, m), 7.29 (2H, s).
1-073
[0244] MS (ES, Pos): 645 (M+1).sup.+, 647 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta. 1.27 (3H, t, J=7.15Hz), 1.40-1.61 (3H, m),
1.70-1.91 (2H, m), 1.92 (6H, s), 2.17-2.23 (2H, m), 2.45 (3 H, s),
2.46-2.49 (3H, m), 2.69-2.81 (2H, m), 3.14-3.23 (2H, m), 3.48-3.59
(2H, m), 4.20 (2H, q, J=7.15Hz), 4.91-4.98 (1H, m), 5.89-5.93 (1H,
m), 6.42 (1H, s), 6.59-6.63 (1H, m), 7.10-7.18 (2H, m), 7.22-7.37
(5H, m).
1-075
[0245] MS (ES, Pos): 598 (M+1).sup.+, 600 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta. 1.18-1.43 (9H, m), 1.50-1.72 (7H, m),
1.83-2.06 (2H, m), 1.92 (6H, s), 2.35 (2H, d, J=6.99Hz), 2.45 (3H,
s), 2.47-2.50 (3H, m), 2.71-2.84 (2H, m), 3.50-3.69 (4H, m), 4.10
(2H, d, J=6.68Hz), 6.42 (1H, s), 6.60-6.63 (1H, m), 7.29 (2H,
s).
1-076
[0246] MS (ES, Pos): 611 (M+1).sup.+, 613 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta. 0.95-1.05 (6H, m), 1.29 (3H, t, J=7.15Hz),
1.48-1.77 (6H, m), 1.83-2.18 (2H, m), 1.92 (6H, s), 2.25 (2H, d,
J=6.99Hz), 2.44 (3H, s), 2.47-2.50 (3H, m), 2.70-2.83 (2H, m),
3.49-3.62 (2H, m), 4.20 (2H, q, J=7.15Hz), 4.60-4.72 (1H, m), 5.85
(1H, d, J=8.24Hz), 6.42 (1H, s), 6.59-6.62 (1H, m), 7.29 (2H,
s).
1-077
[0247] MS (ES, Pos): 556 (M+1).sup.+, 558 (M+3).sup.+; NMR (300
MHz, CDCl.sub.3) .delta. 1.30 (3H, t, J=7.15Hz), 1.50-1.70 (3H, m),
1.85-2.15 (2H, m), 1.92 (6H, s), 2.40-2.50 (2H, m), 2.44 (3 H, s),
2.47-2.50 (3H, m), 2.72-2.84 (2H, m), 3.52-3.62 (2H, m), 4.24 (2H,
q, J=7.15 Hz), 4.64 (2H, s), 6.43 (1H, s), 6.59-6.63 (1H, m), 7.29
(2H, s).
1-078
[0248] MS (ES, Pos): 643 (M+1).sup.+, 645 (M+3).sup.+, 647
(M+5).sup.+, 649 (M+7).sup.+; NMR (300 MHz, CDCl.sub.3) .delta.
1.45-2.05 (9H, m), 2.43-2.46 (3H, m), 2.52 (3H, s), 2.57 (2H, t,
J=7.07Hz), 2.82-3.03 (2H, m), 3.47-3.56 (1H, m), 4.10-4.25 (2H, m),
6.59-6.63 (1H, m), 7.82 (2H, s).
1-082
[0249] MS (ES, Pos): 465 (M+1).sup.+; NMR (300 MHz, CDCl.sub.3)
.delta. 1.20-1.80 (10H, m), 1.85 (3H, s), 2.02 (3H, s), 2.2-2.43
(5H, m), 2.51 (3H, m), 2.92-3.03 (2H, m), 3.13 (6H, s), 3.91-4.04
(2H, m), 6.44-6.48 (1H, m), 7.96 (1H, s).
*2: 1HCl salt *3: The crystal was obtained after standing the
compound purified with column chromatography.
Test Example 1
CRF Receptor Binding Test
[0250] Monkey amygdala membranes were used as a receptor
preparation.
[0251] .sup.125I-CRF was used as .sup.125I-labeled ligand.
[0252] Binding reaction using the .sup.125I-labeled ligand was
carried out by the following method described in The Journal of
Neuroscience, 7, 88 (1987).
Preparation of Receptor Membranes:
[0253] Monkey amygdala was homogenized in 50 mM Tris-HCl buffer (pH
7.0) containing 10 mM MgCl.sub.2, 2 mM EDTA and centrifuged at
48,000.times.g for 20 min, and the precipitate was washed once with
Tris-HCl buffer. The washed precipitate was suspended in 50 mM
Tris-HCl buffer (pH 7.0) containing 10 mM MgCl.sub.2, 2 mM EDTA,
0.1% bovine serum albumin and 100 kallikrein units/ml aprotinin, to
obtain a membrane preparation.
CRF Receptor Binding Test:
[0254] The membrane preparation (0.3 mg protein/ml), .sup.125I-CRF
(0.2 nM) and a test drug were reacted at 25.degree. C. for 2 hours.
After completion of the reaction, the reaction mixture was filtered
by suction through a glass filter (GF/C) treated with 0.3%
polyethylene imine, and the glass filter was washed three times
with phosphate-buffered saline containing 0.01% Triton X-100. After
the washing, the radioactivity of the filter paper was measured in
a gamma counter.
[0255] The amount of .sup.125I-CRF bound when the reaction was
carried out in the presence of 1 .mu.M CRF was taken as the degree
of nonspecific binding of .sup.125I-CRF, and the difference between
the total degree of .sup.125I-CRF binding and the degree of
nonspecific .sup.125I-CRF binding was taken as the degree of
specific .sup.125I-CRF binding. An inhibition curve was obtained by
reacting a definite concentration (0.2 nM) of .sup.125I-CRF with
various concentrations of each test drug under the conditions
described above. A concentration of the test drug at which binding
of .sup.125I-CRF is inhibited by 50% (IC.sub.50) was determined
from the inhibition curve.
[0256] As a result, it was found that compounds I-001, 1-002,
1-003, 1-004, 1-005, 1-006, 1-007, 1-008, 1-009, 1-010, 1-011,
1-012, 1-014, 1-015, 1-016, 1-017, 1-018, 1-019, 1-020, 1-021,
1-022, 1-023, 1-024, 1-025, 1-026, 1-027, 1-028, 1-029, 1-030,
1-031, 1-032, 1-033, 1-034, 1-035, 1-039, 1-042, 1-045, 1-047,
1-048, 1-049, 1-053, 1-056, 1-061, 1-072, 1-073 can be exemplified
as typical compounds having an IC.sub.50 value of 100 nM or
less.
Test Example 2
.delta. Receptor Binding Test
[0257] Rat Brain Membranes were Used as a Receptor Preparation.
[0258] .sup.3H-DPDPE
([.sub.D-Pen.sup.2,.sub.D-Pen.sup.5]-Enkephalin) was used as
.sup.3H-labeled ligand.
[0259] Binding reaction using the .sup.3H-labeled ligand was
carried out by the following method.
Preparation of Receptor Membranes:
[0260] Rat brain was homogenized in 50 mM Tris-HCl buffer (pH 7.4)
containing 10 mM MgCl.sub.2 and 1 mM EDTA, and centrifuged at
48,000.times.g for 20 min, and the precipitate was washed once with
Tris-HCl buffer. The washed precipitate was suspended in 50 mM
Tris-HCl buffer (pH 7.4) containing 10 mM MgCl.sub.2 and 1 mM EDTA,
to obtain a membrane preparation.
Delta Opioid Receptor Binding Test:
[0261] The membrane preparation (1 mg protein/ml), .sup.3H-DPDPE
(1.5 nM) and a test drug were reacted at 25.degree. C. for 70
minutes. After completion of the reaction, the reaction mixture was
filtered by suction through a glass filter (GF/B) treated with 0.3%
polyethylene imine, and the glass filter was washed three times
with 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl.sub.2 and
1 mM EDTA. After the washing, scintillation cocktail was added to
the filters, and the radioactivity of the filter was measured in a
liquid scintillation counter.
[0262] The amount of .sup.3H-DPDPE bound when the reaction was
carried out in the presence of 10 .mu.M naltrindole was taken as
the degree of nonspecific binding of .sup.3H-DPDPE, and the
difference between the total degree of .sup.3H-DPDPE binding and
the degree of nonspecific .sup.3H-DPDPE binding was taken as the
degree of specific .sup.3H-DPDPE binding. An inhibition curve was
obtained by reacting a definite concentration (1.5 nM) of
.sup.3H-DPDPE with various concentrations of each test drug under
the conditions described above. A concentration of the test drug at
which binding of .sup.3H-DPDPE is inhibited by 50% (IC.sub.50) was
determined from the inhibition curve.
[0263] As a result, it was found that compounds I-001, 1-002,
1-003, 1-004, 1-005, 1-006, 1-011, 1-012, 1-016, 1-018, 1-019,
1-020, 1-021, 1-022, 1-025, 1-026, 1-027, 1-032, 1-045, 1-047 and
1-048 can be exemplified as typical compounds having an IC.sub.50
value of 500 nM or less.
EFFECT OF THE INVENTION
[0264] According to the present invention, compounds having a high
affinity for CRF receptors and/or .delta. receptors have been
provided. These compounds have excellent pharmacokinetic properties
including metabolic stability, bioavailability and brain
concentration. These compounds are effective against diseases in
which CRF is considered to be involved, such as depression,
anxiety, Alzheimer's disease, Parkinson's disease, Huntington's
chorea, eating disorder, hypertension, gastrointestinal diseases,
drug dependence, cerebral infarction, cerebral ischemia, cerebral
edema, cephalic external wound, inflammation, immunity-related
diseases, alopecia, irritable bowel syndrome, sleep disorders,
epilepsy, dermatitides, schizophrenia, pain, etc.
* * * * *